Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No No

As of ~~May~~November 1, 2021, the registrant had ~~49,942,069~~50,321,366 shares of Common Stock ($0.001 par value) outstanding.


	March 31, 2021			December 31, 2020			September 30, 2021			December 31, 2020
Assets
Current assets
Cash and cash equivalents	$	98,707		$	107,704		$	136,824		$	107,704
Marketable securities		55,573			67,576			5,229			67,576
Accounts receivable, net		30,365			30,025			29,375			30,025
Inventories		12,676			15,394			14,669			15,394
Prepaid expenses and other current assets		7,301			5,112			6,659			5,112
Total current assets		204,622			225,811			192,756			225,811
Property and equipment, net		19,610			19,538			19,480			19,538
Right-of-use assets		6,147			6,577			5,695			6,577
Total assets	$	230,379		$	251,926		$	217,931		$	251,926
Liabilities and Stockholders’ Deficit
Current liabilities
Accounts payable	$	6,650		$	6,928		$	7,492		$	6,928
Accrued expenses and other current liabilities		21,453			20,008			24,875			20,008
Deferred revenue		10,000			10,000			10,000			10,000
Operating lease liabilities		1,546			1,526			1,619			1,526
Current portion of long-term debt		18,333			16,806			0			16,806
Total current liabilities		57,982			55,268			43,986			55,268
Long-term operating lease liability, net		5,746			6,123			5,328			6,123
Long-term debt, net		39,758			44,114			80,087			44,114
2024 convertible notes, net		165,271			162,786			170,418			162,786
Other long-term liabilities		489			295			489			295
Total liabilities		269,246			268,586			300,308			268,586
Commitments and contingencies
Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2021 and December 31, 2020 and 0 shares issued and outstanding at March 31, 2021 and December 31, 2020		0			0
Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2021 and December 31, 2020 and 0 shares issued and outstanding at September 30, 2021 and December 31, 2020								0			0
Stockholders' deficit
Common stock, $0.001 par value; 100,000,000 shares authorized; 49,941,553 and 49,403,034 shares issued and outstanding, at March 31, 2021 and December 31, 2020, respectively		50			49
Common stock, $0.001 par value; 100,000,000 shares authorized; 50,299,458 and 49,403,034 shares issued and outstanding, at September 30, 2021 and December 31, 2020, respectively								50			49
Additional paid-in capital		771,954			765,607			780,954			765,607
Accumulated other comprehensive loss		(10	)		(11	)		0			(11	)
Accumulated deficit		(810,861	)		(782,305	)		(863,381	)		(782,305	)
Total stockholders' deficit		(38,867	)		(16,660	)		(82,377	)		(16,660	)
Total liabilities and stockholders' deficit	$	230,379		$	251,926		$	217,931		$	251,926

The accompanying notes are an integral part of these condensed consolidated financial statements.


	Three Months Ended						Three Months Ended						Nine Months Ended
	March 31,						September 30,						September 30,
	2021			2020			2021			2020			2021			2020
Revenues
Product revenue, net	$	24,589		$	20,127		$	21,326		$	23,664		$	74,090		$	59,242
Operating expenses
Cost of sales		6,085			2,276			3,727			5,130			14,791			12,887
Research and development		14,047			21,134			14,771			10,092			41,487			43,733
Selling, general and administrative		27,598			29,299			26,986			27,312			81,993			81,341
Total operating expenses		47,730			52,709			45,484			42,534			138,271			137,961
Loss from operations		(23,141	)		(32,582	)		(24,158	)		(18,870	)		(64,181	)		(78,719	)
Other (expense) income
Interest income		300			427			54			62			531			584
Interest expense		(5,189	)		(4,721	)		(5,787	)		(5,125	)		(16,156	)		(14,848	)
Other (expense) income		(526	)		74
Other expense								(421	)		(457	)		(1,270	)		(581	)
Total other (expense) income		(5,415	)		(4,220	)		(6,154	)		(5,520	)		(16,895	)		(14,845	)
Loss before income taxes								(30,312	)		(24,390	)		(81,076	)		(93,564	)
Income tax expense								—			248			—			495
Net loss	$	(28,556	)	$	(36,802	)	$	(30,312	)	$	(24,638	)		(81,076	)		(94,059	)
Net loss per common share, basic and diluted	$	(0.57	)	$	(0.95	)	$	(0.60	)	$	(0.50	)	$	(1.62	)	$	(2.16	)
Weighted average common shares outstanding, basic and diluted		49,841			38,553			50,265			49,298			50,027			43,563
Other comprehensive income (loss):
Unrealized gains (losses) from available-for-sale securities, net of tax of $0		1			(56	)
Unrealized gains (losses) from available-for-sale securities, net of tax of $0								2			(9	)		11			(68	)
Total other comprehensive income (loss)		1			(56	)		2			(9	)		11			(68	)
Comprehensive loss	$	(28,555	)	$	(36,858	)	$	(30,310	)	$	(24,647	)	$	(81,065	)	$	(94,127	)

The accompanying notes are an integral part of these condensed consolidated financial statements.


	Common Stock				Additional		Accumulated Other						Total			Common Stock				Additional			Accumulated Other						Total
	Shares		Par Value		Paid-in- Capital		Comprehensive (Loss) Income			Accumulated Deficit			Stockholders' Deficit			Shares		Par Value		Paid-in- Capital			Comprehensive (Loss) Income			Accumulated Deficit			Stockholders' Deficit
Balance at December 31, 2020		49,403	$	49	$	765,607	$	(11	)	$	(782,305	)	$	(16,660	)		49,403	$	49	$	765,607		$	(11	)	$	(782,305	)	$	(16,660	)
Issuance of common stock, net of issuance costs		134				1,700								1,700			134				1,700									1,700
Issuance of common stock for equity awards, net of shares withheld for taxes		405		1		7								8			405		1		7									8
Stock-based compensation expense						4,640								4,640							4,640									4,640
Net loss											(28,556	)		(28,556	)												(28,556	)		(28,556	)
Other comprehensive income								1						1										1						1
Balance at March 31, 2021		49,942	$	50	$	771,954	$	(10	)	$	(810,861	)	$	(38,867	)		49,942	$	50	$	771,954		$	(10	)	$	(810,861	)	$	(38,867	)
Issuance of common stock for equity awards, net of shares withheld for taxes																	46				—									—
Employee stock purchase plan																	118				921									921
Stock-based compensation expense																					3,975									3,975
Net loss																											(22,208	)		(22,208	)
Other comprehensive income																								8						8
Balance at June 30, 2021																	50,106	$	50	$	776,850		$	(2	)	$	(833,069	)	$	(56,171	)
Issuance of common stock for equity awards, net of shares withheld for taxes																	193				(92	)								(92	)
Stock-based compensation expense																					4,196									4,196
Net loss																											(30,312	)		(30,312	)
Other comprehensive income																								2						2
Balance at September 30, 2021																	50,299	$	50	$	780,954		$	—		$	(863,381	)	$	(82,377	)

The accompanying notes are an integral part of these condensed consolidated financial statements.


	Three Months Ended						Nine Months Ended
	March 31,						September 30,
	2021			2020			2021			2020
Cash flows from operating activities
Net loss	$	(28,556	)	$	(36,802	)	$	(81,076	)	$	(94,059	)
Adjustments to reconcile net loss to cash used in operating activities
Depreciation		521			198			1,573			1,295
Amortization of right-of-use assets		430			401			1,315			1,224
Stock-based compensation expense		4,640			4,651			12,811			13,397
Provision for inventory		540			—			1,773			0
Non cash interest expense		226			106			540			518
Amortization (accretion) of premium (discount) on marketable securities		251			(59	)		441			(18	)
Loss on disposal of fixed assets		—			262			0			262
Loss on debt extinguishment								502			—
Amortization of debt discount and debt issuance costs		2,485			2,262			7,842			6,947
Premium paid on securities purchased		3			—			(54	)		(534	)
Changes in operating assets and liabilities:
Accounts receivable		(340	)		6,753			650			9,216
Inventory		2,178			(3,101	)		(1,048	)		(1,063	)
Prepaid expenses and other current assets		(2,189	)		(441	)		(1,547	)		(496	)
Accounts payable		124			(3,035	)		980			(6,693	)
Accrued expenses and other current liabilities		1,570			1,025			4,992			216
Deferred revenue								0			10,000
Lease liabilities		(357	)		(417	)		(1,135	)		(1,031	)
Net cash used in operating activities		(18,474	)		(28,197	)		(51,441	)		(60,819	)
Cash flows from investing activities
Purchases of property and equipment		(801	)		(3,244	)		(1,737	)		(8,860	)
Proceeds from sale of fixed assets								0			13
Purchases of marketable securities		(2,000	)		—			(5,175	)		(56,216	)
Sale and redemption of marketable securities		13,750			41,198			67,146			54,398
Net cash provided by investing activities		10,949			37,954
Net cash provided by (used in) investing activities								60,234			(10,665	)
Cash flows from financing activities
Proceeds from borrowings under term loan								55,000			15,000
Payments on notes payable								(56,875	)		—
Proceeds from revolving line of credit		—			20,000			20,000			20,000
Repayments of revolving line of credit								0			(15,000	)
Proceeds from the offering of common stock								0			97,289
Proceeds from issuance of common stock (net of issuance costs)		1,700		—				1,700			—
Payments of public offering costs		(125	)		—			(125	)		(400	)
Payments on notes payable		(3,055	)	—
Proceeds from the exercise of stock options		8			9
Net cash (used in) provided by financing activities		(1,472	)		20,009
Net (decrease) increase in cash and cash equivalents		(8,997	)		29,766
Payment of debt issuance costs								(210	)		—
Proceeds from the exercise of stock options (net of shares withheld for taxes)								(84	)		88
Proceeds from employee stock purchase plan								921			891
Net cash provided by financing activities								20,327			117,868
Net increase in cash and cash equivalents								29,120			46,384
Cash and cash equivalents at beginning of period		107,704			82,253			107,704			82,253
Cash and cash equivalents at end of period	$	98,707		$	112,019		$	136,824		$	128,637
Non-cash investing and financing activities
Non-cash operating, investing and financing activities
Right-of-use asset obtained in exchange for operating lease obligation								433			—
Purchases of property and equipment in accounts payable and accrued expenses		30			1,436			15			870
Public offering costs in accounts payable and accrued expenses								0			125
Supplemental disclosures of cash flow information
Cash paid for interest		955			703			6,483			6,042

The accompanying notes are an integral part of these condensed consolidated financial statements.

1. Overview and Nature of the Business

~~Overview and Nature of the Business~~

Flexion Therapeutics, Inc. (“Flexion” or the “Company”) was incorporated under the laws of the state of Delaware on November 5, ~~2007.~~2007. Flexion is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, or OA, the most common form of arthritis. The Company has an approved product, ZILRETTA®, which it markets in the United States. ZILRETTA is the first and only extended-release, intra-articular, or IA (meaning in the joint), injection indicated for the management of OA knee pain. ZILRETTA is a non-opioid therapy that employs Flexion’s proprietary microsphere technology to provide pain relief. The pivotal Phase 3 trial, on which the approval of ZILRETTA was based, showed that ZILRETTA met the primary endpoint of pain reduction at Week 12, with statistically significant pain relief extending through Week 16. The Company also has two pipeline programs focused on the local treatment of musculoskeletal conditions: FX201, an investigational IA gene therapy product candidate in clinical development for the treatment of OA, and FX301, a locally administered peripheral nerve block product candidate in clinical development ~~which is being investigated as a locally administered peripheral nerve block~~ for the control of post-operative pain.

The Company is subject to risks and uncertainties common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations. Successfully commercializing ZILRETTA requires significant sales and marketing efforts and the Company’s pipeline programs will require significant additional research and development efforts, including extensive preclinical and clinical testing. These activities will in turn require significant amounts of capital, qualified personnel, and adequate infrastructure. There can be no assurance as to when, if ever, the Company will generate sales of ZILRETTA that are significant enough to achieve profitability or if the development efforts supporting the Company’s pipeline, including future clinical trials, will be successful.

Proposed Acquisition by Pacira BioSciences, Inc.

On October 11, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Pacira BioSciences, Inc., a Delaware corporation (“Pacira”), and Oyster Acquisition Company Inc., a Delaware corporation and wholly owned subsidiary of Pacira (“Purchaser”). Pursuant to the Merger Agreement, on October 22, 2021, Purchaser commenced a tender offer (the “Offer”) to purchase each issued and outstanding share of the Company’s common stock (the “Shares”) at an offer price of (i) $8.50 per Share in cash, net of applicable withholding taxes and without interest, plus (ii) one non-transferable contractual contingent value right per Share, which will represent the right to receive one or more contingent payments up to $8.00 in the aggregate, in cash, net of applicable withholding taxes and without interest, upon the achievement of specified milestones on or prior to December 31, 2030.

Promptly following the completion of the Offer, upon the terms and subject to the conditions of the Merger Agreement, Purchaser will merge with and into the Company (the “Merger”), with the Company continuing as the surviving corporation and as a wholly owned subsidiary of Pacira. The Merger Agreement contemplates that the Merger will be effected pursuant to Section 251(h) of the Delaware General Corporation Law, which permits completion of the Merger without a vote of the holders of common stock upon the acquisition by Purchaser of a majority of the aggregate voting power of common stock. As a result of the Merger, the Company will cease to be a publicly traded company.

The Merger Agreement contains customary representations and warranties. The Merger is expected to close before the end of the calendar year 2021, subject to the satisfaction or waiver of customary closing conditions, including, among others, that the number of Shares tendered in the Offer represent at least one Share more than 50% of the total number of Shares at the time of the expiration of the Offer. The Merger Agreement provides Pacira and the Company with certain termination rights and, under certain circumstances, may require the Company to pay Pacira a termination fee of $18.0 million.

For additional information related to the Merger Agreement, refer to the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the Securities and Exchange Commission on October 22, 2021, together with the exhibits and annexes thereto and as amended or supplemented from time to time.

The Company recorded acquisition-related costs of approximately $0.7 million for each of the three and nine months ended September 30, 2021, primarily for outside legal and external financial advisory fees associated with the pending acquisition by Pacira. These costs were recorded in general and administrative expense in the Company’s condensed consolidated statements of operations and comprehensive loss in the respective reporting periods. Additional acquisition-related costs are expected to be incurred through the closing of the Merger.

Going Concern

The accompanying condensed consolidated financial statements have been prepared on a basis ~~which~~that assumes that the Company will continue as a going concern and ~~which~~that contemplates the realization of assets and satisfaction of liabilities and commitments in the

normal course of business. The Company has incurred recurring losses and negative cash flows from operations. As of ~~March 31,~~September 30, 2021, the Company had cash, cash equivalents, and marketable securities of approximately ~~$154.3~~$142.1 million.

Management believes that current cash, cash equivalents, and marketable securities on hand at March 31, 2021, will be sufficient to fund operations and debt obligations for at least the next 12 months from the issuance date of these financial statements. The Company currently expects to be able to maintain the liquidity threshold in the amended and restated credit agreement described in Note 9 for at least 12 months following the issuance of these financial statements. As a result, the revenue covenant under the amended and restated credit and security agreement is not expected to be applicable through 12 months from the issuance of the financial statements. As of March 31, 2021, the Company was in compliance with all covenants under the amended and restated credit and security agreement.

The Company’s operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID-19”) ~~and the resulting volatility and uncertainty it has caused.~~. In March 2020, the World Health Organization declared COVID-19 a pandemic and recommended containment and mitigation measures worldwide. The COVID-19 pandemic has caused significant volatility and uncertainty, which could result in a prolonged economic downturn that has disrupted and is expected to continue to disrupt the Company’s business. While there have been no material asset impairments recorded to date, any prolonged material future disruptions to the work of the Company’s employees, suppliers, contract manufacturers, or vendors, or to the operations of physicians that administer ZILRETTA could negatively impact the Company’s operations, availability of supplies, carrying value of assets, operating results, or cash flows.

The future viability of the Company is dependent on its ability to fund its operations through sales of ZILRETTA, and/or raising additional capital, such as through debt or equity offerings, as needed. If the Company is unable to grow sales of ZILRETTA in future periods, it is possible that the Company may not maintain compliance with the revenue covenant, in the event it applies, in future periods. As a result, the Company could be required to repay its outstanding borrowings under the term loan and revolving credit facility and would seek additional financing. The Company may not be able to obtain financing on acceptable terms, or at all. In particular, as a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility and disruptions, including declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any additional debt or equity financing more difficult, more costly, and more dilutive. If the Company is unable to obtain funding on a timely basis, the Company may need to curtail its operations, including the commercialization of ZILRETTA, and/or reduce the scope of, or delay certain research and development activities, including the FX201 or FX301 programs, which could adversely affect its prospects.

7In accordance with the amended and restated credit and security agreement described in Note 9, if the Company’s liquidity decreases below $100.0 million, the Company will need to comply with a minimum revenue covenant and all amounts received from customer collections will be applied to immediately reduce the Company’s revolving credit facility. The minimum revenue covenant is set annually and is applied to the trailing six-months of net revenue and is determined based on the Company’s approved forecast, as determined by the Lenders. The amended and restated credit and security agreement also has a material adverse event clause. If the minimum revenue covenant becomes applicable and the Company fails to comply with it, or a material adverse change as defined in the agreement occurs, the amounts due under the amended and restated credit and security agreement could be declared immediately due and payable, resulting in the Company immediately needing additional funds. As of September 30, 2021, the Company was in compliance with all financial covenants under the amended and restated credit and security agreement.

If the Company is unable to grow sales of ZILRETTA in future periods, it is possible that the Company may not maintain compliance with the revenue covenant, in the event it applies, in future periods, which would require the Company to repay its outstanding borrowings under the term loan and revolving credit facility. Given the recent decrease in revenue as compared to the Company’s expectations, the Company expects that absent raising additional capital through financing or other transactions its cash balance is likely to decrease below $100.0 million within the next twelve months, and the Company believes there is substantial risk that it would fail to meet the minimum revenue covenant at that time or shortly thereafter if demand for ZILRETTA does not increase in line with its expectations. If the Company is or expects to be subject to and unable to meet the minimum revenue covenant, the Company would plan to request a waiver from the lenders, although there can be no assurances that such a request would be granted or would not be conditioned on additional terms or concessions. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued.

Management’s plans that would be intended to mitigate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern include reducing operating expenses through hiring and travel freezes, delaying, reducing, or ceasing all research and development activities outside of the ongoing clinical trials, reduction of certain external expenses, and elimination of non-essential operating expenses, requesting a waiver of the minimum revenue covenant from the lenders, and remaining opportunistic with respect to raising additional capital through financing or other transactions. However, as the Company is expecting to close the planned merger with Pacira prior to the end of 2021, none of the above actions have been taken or have been approved to be taken and therefore cannot be considered in management’s going concern evaluation as a mitigating action.

The Company has concluded that without taking into consideration the planned Merger with Pacira, management’s plans do not alleviate the substantial doubt about the Company’s ability to continue as a going concern. As the planned Merger with Pacira has not occurred as of the issuance of these financial statements, it also cannot be considered within management’s plans to alleviate the conditions raised around substantial doubt. As a result, in accordance with the requirements of ASC 205-40, management has concluded that it is required to disclose that substantial doubt exists about the Company’s ability to continue as a going concern for one year from the date these financial statements are issued.

2. Summary of Significant Accounting Policies

~~Summary of Significant Accounting Policies~~

The accompanying condensed consolidated financial statements as of ~~March 31,~~September 30, 2021, and for the three and nine months ended ~~March 31,~~September 30, 2021 and 2020, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and Generally Accepted Accounting Principles (“GAAP”) for consolidated financial information including

the accounts of the Company and its wholly owned subsidiary after elimination of all significant intercompany accounts and transactions. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, these condensed consolidated financial statements reflect all adjustments ~~which~~that are necessary for a fair statement of the Company’s financial position and results of its operations, as of and for the periods presented. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 10, 2021.

The information presented in the condensed consolidated financial statements and related notes as of ~~March 31,~~September 30, 2021, and December 31, 2020, and for the three and nine months ended ~~March 31,~~September 30, 2021 and 2020, is unaudited. The December 31, 2020, condensed consolidated balance sheet included herein was derived from the audited financial statements as of that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements.

Interim results for the three and nine months ended ~~March 31,~~September 30, 2021, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021, or any future period.

Recent Accounting Pronouncements

Accounting Standards Recently Issued

In August 2020, the FASB issued ASU No. 2020-06, (“ASU 2020-06”). The new standard simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. The new guidance reduced the number of accounting models for convertible debt and convertible preferred stock instruments and made certain disclosure amendments intended to improve the information provided to users. The guidance also amended the derivative guidance for the “own stock” scope exception, which exempts qualifying instruments from being accounted for as derivatives if certain criteria are met. Finally, the standard changed the way certain convertible instruments are treated when calculating earnings per share. The standard is effective for the Company for fiscal years, and the interim periods within those years, beginning after December 15, 2021, and early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-06 on the Company’s condensed consolidated financial statements.

Consolidation

~~Consolidation~~

The accompanying condensed consolidated financial statements include the Company and its wholly owned subsidiary, Flexion Therapeutics Securities Corporation. The Company has eliminated all intercompany transactions for the three and nine months ended ~~March 31,~~September 30, 2021, and the year ended December 31, 2020.

Revenue Recognition

On October 6, 2017, the U.S. Food and Drug Administration (“FDA”) approved ZILRETTA. The Company entered into a limited number of arrangements with specialty distributors and a specialty pharmacy in the U.S. to distribute ZILRETTA. The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) Topic 606 - Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration ~~which~~that the entity expects to be entitled to in exchange for those goods or services.

To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract with a customer under Topic 606, including when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Product Revenue, Net

The Company primarily sells ZILRETTA to specialty distributors and a specialty pharmacy, who then subsequently resell ZILRETTA to physicians, clinics, and certain medical centers or hospitals. The Company also contracts directly with healthcare providers and intermediaries such as Group Purchasing Organizations (“GPOs”). In addition, the Company enters into arrangements with government payers that provide for government mandated rebates and chargebacks with respect to the purchase of ZILRETTA.

The Company recognizes revenue on product sales when the customer obtains control of the ~~Company's~~Company’s product, which occurs at a point in time (upon delivery to the customer). The Company has determined that the delivery of ZILRETTA to its customers constitutes a single performance obligation. There are no other promises to deliver goods or services beyond what is specified in each accepted customer order. The Company has assessed the existence of a significant financing component in the agreements with its customers. The trade payment terms with customers do not exceed one year, and therefore the Company has elected to apply the

practical expedient and no amount of consideration has been allocated as a financing component. Product revenues are recorded net of applicable reserves for variable consideration, including discounts and allowances.

Transaction Price, including Variable Consideration

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, government chargebacks, discounts and rebates, and other incentives, such as voluntary patient assistance, and other ~~fee for service~~fee-for-service amounts that are detailed within contracts between the Company and its customers relating to the Company’s sale of its products. These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). These estimates take into consideration a range of possible outcomes ~~which~~that are probability-weighted in accordance with the expected value method in Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.

The amount of variable consideration ~~which~~that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s original estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.

Service Fees and Allowances

The Company compensates its customers and GPOs for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company’s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations and comprehensive loss through ~~March 31,~~September 30, 2021, as well as a reduction to trade receivables, net on the condensed consolidated balance sheets.

Product Returns

Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product’s expiration date. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as within accrued expenses and other current liabilities, net, on the condensed consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. ~~The~~Historically, the Company has received an immaterial amount of returns. In the third quarter of 2021, there was a significant increase in actual and expected product returns from specialty distributors of product that was never sold through to ~~date~~healthcare providers. This is due to the fact that the majority of product sold during the third quarter had between 3-4 months of expiry remaining. The vast majority of the returns related to product that was sold to the specialty distributors during the third quarter of 2021 and ~~believes that~~resulted in a $2.0 million reduction of revenue in the third quarter of 2021. In addition, the Company increased its estimate of future returns relating to short-dated product, which resulted in an additional $1.4 million reduction in revenue in the third quarter of ~~ZILRETTA will be minimal.~~2021.

Chargebacks

Chargebacks for fees and discounts to qualified government healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified VA hospitals and 340b entities at prices lower than the list prices charged to customers who directly purchase the product from the Company. The 340b Drug Discount Program is a U.S. federal government program created in 1992 that requires drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices. Customers charge the Company for the difference between what they pay for the product and the statutory selling price to the qualified government entity. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and trade receivables, net. Chargeback amounts are generally determined at the time of resale to the qualified government healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period-end that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit.

Government Rebates

The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability ~~which~~that is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability

910

under the Medicare Part D program. The Company estimates its exposure to utilization from the Medicare Part D coverage gap discount program to be immaterial. For Medicaid programs, the Company estimates the portion of sales attributed to Medicaid patients and records a liability for the rebates to be paid to the respective state Medicaid programs. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but ~~which~~that remains in the distribution channel inventories at the end of each reporting period.

Purchaser/Provider Discounts and Rebates

The Company offers rebates to eligible purchasers and healthcare providers that are variable based on volume of product purchased. Rebates are based on actual purchase levels during the rebate purchase period. In the third quarter of 2021, the Company implemented an off-invoice discount (“OID”) program whereby providers receive the discounted price immediately upon purchase, rather than having to wait until the end of the quarter for a rebate payment. Specialty distributors and other customers charge the Company for the difference between what they pay for the product (list price) and the net selling price after taking into account the OID. Chargeback amounts are generally determined at the time of resale to the eligible healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Reserves for commercial chargebacks consist of credits that the Company expects to issue for units sold to qualified healthcare providers but for which no chargeback has been submitted, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a ~~current~~current liability ~~which~~that is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets.

Other Incentives

Other incentives ~~which~~that the Company offers include voluntary patient assistance programs, such as the co-pay assistance program, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payers. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability ~~which~~that is included as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.

To date, the Company’s only source of product revenue has been from the U.S. sales of ZILRETTA, which it began shipping to customers in October 2017.

The following table summarizes activity in each of the product revenue allowance and reserve categories for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 and 2020:


(In thousands)	Service Fees, Allowances and Chargebacks			Government Rebates and Other Incentives			Product Returns			Purchaser/Provider Discounts and Rebates			Total			Service Fees, Allowances and Chargebacks			Government Rebates and Other Incentives			Product Returns			Purchaser/ Provider Discounts and Rebates			Total
Balance as of December 31, 2020	$	1,733		$	530		$	628		$	1,832		$	4,723		$	1,733		$	530		$	628		$	1,832		$	4,723
Provision related to sales in the current quarter		2,188			383			151			2,703			5,425			2,188			383			151			2,703			5,425
Credits and payments made		(1,969	)		(266	)		(9	)		(1,832	)		(4,076	)		(1,969	)		(266	)		(9	)		(1,832	)		(4,076	)
Adjustments related to prior period sales		—			—			(111	)		—			(111	)		—			—			(111	)		—			(111	)
Balance as of March 31, 2021		1,952			647			659			2,703			5,961			1,952			647			659			2,703			5,961
Provision related to sales in the current quarter																	2,682			424			179			3,100			6,385
Credits and payments made																	(2,527	)		(311	)		(86	)		(2,711	)		(5,635	)
Adjustments related to prior period sales																	(10	)		—			—			—			(10	)
Balance as of June 30, 2021																$	2,097		$	760		$	752		$	3,092		$	6,701
Provision related to sales in the current quarter																	2,538			290			3,130			3,245			9,203
Credits and payments made																	(2,859	)		(401	)		(1,331	)		(5,182	)		(9,773	)
Adjustments related to prior period sales																	—			—			291			—			291
Balance as of September 30, 2021																$	1,776		$	649		$	2,842		$	1,155		$	6,422

Balance as of December 31, 2019	$	1,847		$	248		$	402		$	1,656		$	4,153		$	1,847		$	248		$	402		$	1,656		$	4,153
Provision related to sales in the current quarter		1,590			254			114			526			2,484			1,590			254			114			526			2,484
Credits and payments made		(1,852	)		(199	)		(10	)		(1,656	)		(3,717	)		(1,852	)		(199	)		(10	)		(1,656	)		(3,717	)
Adjustments related to prior period sales	—				95		—			—				95			—			95			—			—			95
Balance as of March 31, 2020		1,585			398			506			526			3,015			1,585			398			506			526			3,015
Provision related to sales in the current quarter																	1,417			133			98			892			2,540
Credits and payments made																	(1,172	)		(262	)		(1	)		(528	)		(1,963	)
Adjustments related to prior period sales																	—			90			—			2			92
Balance as of June 30, 2020																$	1,830		$	359		$	603		$	892		$	3,684
Provision related to sales in the current quarter																	2,270			265			136			1,314			3,985
Credits and payments made																	(2,585	)		(198	)		(21	)		(894	)		(3,698	)
Adjustments related to prior period sales																	—			40			—			2			42
Balance as of September 30, 2020																$	1,515		$	466		$	718		$	1,314		$	4,013

License Agreement – On March 30, 2020, the Company entered into an exclusive license agreement with Hong Kong Tainuo Pharma Ltd. (“HK Tainuo”) and Jiangsu Tainuo Pharmaceutical Co. Ltd. (“Jiangsu Tainuo”), a subsidiary of China Shijiazhuang Pharmaceutical Co, Ltd., for the development and commercialization (other than manufacturing) of ZILRETTA in Greater China (consisting of mainland China, Hong Kong and Macau, and Taiwan). Under the terms of the agreement, HK Tainuo paid the Company an upfront payment of ~~$10.0~~$10.0 million, of which ~~$5.0~~$5.0 million was received as of June 30, 2020, and the remaining ~~$5.0~~$5.0 million was received as of September 30, 2020. The Company is also eligible to receive up to ~~$32.5~~$32.5 million in aggregate development, regulatory, and commercial sales milestone payments. All payments received from HK Tainuo are subject to ~~the~~ applicable Hong Kong withholding taxes. HK Tainuo is responsible for the clinical development, product registration, and commercialization of ZILRETTA in Greater China, and Jiangsu Tainuo serves as the guarantor of HK Tainuo’s obligations and responsibilities under the agreement. The Company is solely responsible for the manufacture and supply of ZILRETTA to HK Tainuo for all clinical and commercial activities. The terms related to product manufacturing and supply, including pricing and minimum purchase requirements agreed to in the license agreement, will be covered by a separate supply agreement, which has not yet been finalized. All amounts owed to the Company are nonrefundable and non-creditable once paid. Unless terminated earlier in accordance with its terms, the license agreement continues in effect in perpetuity or as long as HK Tainuo or Jiangsu Tainuo continue to sell ZILRETTA in Greater China. Either party may terminate the agreement prior to expiration in the event of a material breach if not cured within 60 days from the date of notice of such breach (30 days in the case of payment obligations), or either party files for bankruptcy. The Company also has the right to terminate the agreement if HK Tainuo, Jiangsu Tainuo, or any affiliate of each commences any action or proceeding that challenges the validity, enforceability, or scope of any Company patent in Greater China. Upon any such termination, the license granted to HK Tainuo will

terminate and all know-how and patents will revert back to the Company. The Company concluded that the license and supply obligations were not distinct performance obligations, and therefore the transaction price will be recognized as revenue as the

Company’s supply obligation is fulfilled over the term of the supply agreement, which has not yet commenced. NaN revenue was recognized associated with this contract as of ~~March 31,~~September 30, 2021. The proceeds associated with the upfront payment have been recorded in short-term deferred revenue on the Company’s condensed consolidated balance sheet as of ~~March 31,~~September 30, 2021, as there is uncertainty around the timing of when the revenue will be recognized. The Company will re-evaluate the classification of deferred revenue when the supply agreement is finalized.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities, revenue and expenses, and related disclosures. The Company bases estimates and judgments on historical experience and on various other factors that it believes to be reasonable under the circumstances. The most significant estimates in these condensed consolidated financial statements include estimates related to revenue recognition and accrued expenses related to preclinical and clinical development costs. The Company’s actual results may differ from these estimates under different assumptions or conditions. The Company evaluates its estimates on an ongoing basis. Changes in estimates are reflected in reported results in the period in which they become known by the Company’s management.

The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations, and financial condition, including sales, expenses, reserves and allowances, clinical trials, research and development expenses, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national, and international customers and markets. The Company has made estimates of the impact of COVID-19 within its financial statements, and there may be changes to those estimates in future periods.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation and amortization expense is recognized using the straight-line method over the following estimated useful lives:


	Estimated Useful Life (Years)
Computers, office equipment, and minor computer software		3
Computer software		7
Manufacturing equipment	~~7-10~~	7-10
Furniture and fixtures		5

Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. Costs of major additions and improvements are capitalized and depreciated on a straight-line basis over their useful lives. Repairs and maintenance costs are expensed as incurred. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to income. Property and equipment includes construction-in-progress that is not yet in service.

Foreign Currencies

The Company maintains a bank account denominated in British Pounds. All foreign currency payables and cash balances are measured at the applicable exchange rate at the end of the reporting period. All associated gains and losses from foreign currency transactions are reflected in the consolidated statements of operations.

Leases

~~Leases~~

The Company determines if an arrangement is a lease at contract inception. Operating lease assets represent a right to use an underlying asset for the lease term and operating lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease liabilities with a term greater than one year and their corresponding right-of-use assets are recognized on the balance sheet at the commencement date of the lease based on the present value of lease payments over the expected lease term. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The Company made an accounting policy election to expense leases with a term of one year or less on a straight-line basis over the lease term. To date, the Company has not identified any material short-term leases, either individually or in the aggregate.

As the Company’s leases do not provide an implicit rate, the Company utilized the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company estimated the incremental borrowing rate based on a yield curve analysis of companies with a similar credit rating to its own, which was calculated using a number of financial ratios and qualitative considerations of the Company’s business. The yields on the Company’s currently outstanding debt (the convertible senior notes and term loan described below) were

also used as inputs to the analysis to calculate a spread, adjusted for factors that reflect the profile of secured borrowing over the expected term of the lease.

The components of a lease should be split into three categories: lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, utilities, performance of manufacturing services, purchase of inventory, etc.), and non-components (e.g., property taxes, insurance, etc.). Then the fixed contract consideration (including any related to non-components) must be allocated based on fair values to the lease components and non-lease components. Although separation of lease and non-lease components is required, certain practical expedients are available to entities. Entities electing the practical expedient would not separate lease and non-lease components. Rather, they would account for each lease component and the related non-lease component together as a single component. The Company has elected to use this practical expedient for its real estate leases and account for each lease component and related non-lease component as one single component. In contrast, the Company has elected not to apply the practical expedient for its lease of manufacturing space at Patheon and has instead allocated consideration between the lease and non-lease components of the contract. The Company calculated the fair value of the lease component using publicly available information to identify comparable rentals in the same geographic area. The remainder of the consideration was allocated to the non-lease components.

3. Fair Value of Financial Assets and Liabilities

3.	~~Fair Value of Financial Assets and Liabilities~~

The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of ~~March 31,~~September 30, 2021 and December 31, 2020, and indicate the level of the fair value hierarchy utilized to determine such fair value:


	Fair Value Measurements as of March 31, 2021 Using:								Fair Value Measurements as of September 30, 2021 Using:
(In thousands)	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	78,021	$	—	$	—	$	78,021	$	108,686	$	0	$	0	$	108,686
Marketable securities		—		55,573		—		55,573		0		5,229		0		5,229
	$	78,021	$	55,573	$	—	$	133,594	$	108,686	$	5,229	$	0	$	113,915


	Fair Value Measurements as of December 31, 2020 Using:
(In thousands)	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	79,148	$	6,832	$	0	$	85,980
Marketable securities		0		67,576		0		67,576
	$	79,148	$	74,408	$	0	$	153,556

As of ~~March 31,~~September 30, 2021 and December 31, 2020, the Company’s cash equivalents that are invested in money market funds are valued using Level 1 inputs based on quoted prices for identical securities in active markets. The Company’s marketable securities are valued using Level 2 inputs and primarily rely on quoted prices in active markets for similar marketable securities. Amortization and accretion of discounts and premiums are recorded in other income.

The Company has a term loan outstanding under its ~~2019~~2021 credit facility with Silicon Valley Bank as agent, MidCap Financial Trust, and ~~Flexpoint MCLS Holdings, LLC~~MidCap Funding XIII Trust (the ~~“2019~~“2021 term loan”), as well as a revolving credit facility. The amount outstanding on the ~~2019~~2021 term loan is reported at its carrying value in the accompanying balance sheet as of ~~March 31,~~September 30, 2021. The Company determined the fair value of the ~~2019~~2021 term loan using an income approach that utilizes a discounted cash flow analysis based on current market interest rates for debt issuances with similar remaining years to maturity, adjusted for credit risk. The ~~2019~~2021 term loan was valued using Level 2 inputs as of ~~March 31,~~September 30, 2021. The result of the calculation yielded a fair value that approximates its carrying value. The Company also concluded that the carrying value of the revolving credit facility approximates fair value because of the short-term maturity of this debt instrument.

On May 2, 2017, the Company issued ~~3.375%~~3.375% convertible senior notes due 2024 (the “2024 Convertible Notes”) with embedded conversion features. The Company estimated the fair value of the 2024 Convertible Notes using a discounted cash flow approach to derive the value of a debt instrument using the expected cash flows and the estimated yield related to the convertible notes. The significant assumptions used in estimating the expected cash flows were: the estimated market yield based on an implied yield and credit quality analysis of a term loan with similar attributes and the average implied volatility of the Company’s traded and quoted options available as of May 2, 2017. The Company recorded approximately ~~$136.7~~$136.7 million as the fair value of the liability on May 2, 2017, with a corresponding amount recorded as a discount on the initial issuance of the 2024 Convertible Notes of approximately ~~$64.5~~$64.5 million. The debt discount was recorded to equity and is being amortized to the debt liability over the life of the 2024 Convertible Notes using the effective interest method.

The fair value of the 2024 Convertible Notes, which differs from their carrying value, is influenced by interest rates, stock price, and stock price volatility and is determined by prices for the 2024 Convertible Notes observed in market trading. The market for trading of the 2024 Convertible Notes is not considered to be an active market, and therefore the estimate of fair value is based on Level 2 inputs. The estimated fair value of the 2024 Convertible Notes, face value of ~~$201.3~~$201.3 million, was ~~$181.5~~$179.8 million at ~~March 31,~~September 30, 2021.

4. Marketable Securities

~~Marketable Securities~~

As of ~~March 31,~~September 30, 2021 and December 31, 2020, the fair value of available-for-sale marketable securities by type of security was as follows:

As of ~~March 31,~~September 30, 2021 and December 31, 2020, marketable securities consisted of ~~$55.6~~$5.2 million and ~~$67.6~~$67.6 million, respectively, of investments that mature within 12 months. There were 0 investments with maturities greater than 12 months as of ~~March 31,~~September 30, 2021, and December 31, 2020. The Company assesses its available-for-sale marketable securities for impairment on a quarterly basis in accordance with ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. There were 0 material impairments of the Company’s available-for-sale marketable securities measured and carried at fair value during the three and nine months ended ~~March 31,~~September 30, 2021.

5. Prepaid Expenses and Other Current Assets

~~Prepaid Expenses and Other Current Assets~~

Prepaid expenses and other current assets consisted of the following as of ~~March 31,~~September 30, 2021, and December 31, 2020:

(In thousands)

March 31,
2021

December 31,
2020

Prepaid expenses

$
6,440

$
4,346

Deposits

113

112

Interest receivable on marketable securities

304

246

Other

444

408

Total prepaid expenses and other current assets

$
7,301

$
5,112

Inventory consisted of the following as of ~~March 31,~~September 30, 2021, and December 31, 2020:

Finished goods manufactured by the Company have a shelf life of approximately 24 months from the date of manufacture.

The Company reduces its inventory to net realizable value for potentially excess, dated, or obsolete inventory based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life. During the ~~three~~nine months ended ~~March 31,~~September 30, 2021, the Company expensed ~~$3.1~~$5.2 million to cost of sales for unabsorbed manufacturing and overhead costs related to the operation of the United Kingdom facility at Patheon UK Limited. In addition, cost of sales for the three and nine months ended ~~March 31,~~September 30, 2021, included ~~a charge~~charges of ~~$0.5~~$1.2 million and $1.8 million, respectively, resulting from the write-down of short-dated ZILRETTA inventory that iswill not ~~expected to~~ be sold prior to expiry.

7. Property and Equipment, Net

~~Property and Equipment, Net~~

Property and equipment, net, as of ~~March 31,~~September 30, 2021, and December 31, 2020, consisted of the following:

Depreciation for the three and nine months ended ~~March 31,~~September 30, 2021, ~~and 2020,~~ was approximately ~~$0.5~~$0.5 million and ~~$0.2~~$1.6 million, ~~respectively.~~ respectively, compared to $0.5 and $1.3 million, respectively, for the same periods in the prior year. NaN property and equipment was disposed of during the ~~three~~nine months ended ~~March 31,~~September 30, 2021. The ~~company~~Company disposed of 1 piece of equipment during the ~~three~~nine months ended ~~March 31,~~September 30, 2020, and recorded a loss on the disposal of ~~$0.3~~$0.3 million. As of ~~March 31,~~September 30, 2021, construction in progress consisted primarily of equipment purchases related to the expansion of the Company’s manufacturing capabilities at its contract manufacturer, Patheon U.K. Limited.

8. Accrued Expenses and Other Current Liabilities

~~Accrued Expenses and Other Current Liabilities~~

Accrued expenses and other current liabilities consisted of the following as of ~~March 31,~~September 30, 2021, and December 31, 2020:

(In thousands)

March 31,
2021

December 31,
2020

Research and development

$
3,565

$
1,856

Payroll and other employee-related expenses

6,301

10,674

Professional services fees

2,688

2,094

Accrued interest

3,145

1,464

Product revenue reserves

4,010

2,990

Accrual for employee stock purchase plan

733

235

Foreign withholding taxes payable

495

495

Other

516

200

Total accrued expenses and other current liabilities

$
21,453

$
20,008

On August 4, 2015, the Company entered into a credit and security agreement with MidCap Financial Trust, as agent, and MidCap Financial Funding XIII Trust and Silicon Valley Bank, as lenders, to borrow up to ~~$30.0~~$30.0 million in term loans (the “2015 term loan”). On August 2, 2019, the Company terminated the credit and security agreement and concurrently entered into an amended and restated credit and security agreement (the ~~“amended and restated credit and security agreement”~~“Existing Credit Agreement”) with Silicon Valley Bank as agent, MidCap Financial Trust, Flexpoint MCLS Holdings, LLC, and the other lenders from time to time party thereto, ~~(collectively, the “Lenders”),~~ providing for a term loan of ~~$40.0~~$40.0 million and a revolving credit facility of up to ~~$20.0~~$20.0 million, both of which mature on January 1, 2024 ~~(the “Maturity Date”)~~. The Company concurrently borrowed the $40.0 million term loan and used ~~$7.7~~$7.7 million of the proceeds to repay the remaining amount owed on the 2015 term loan.

On May 18, 2020, the Company borrowed $15.0 million under a new term loan advance and immediately used the proceeds to repay an equal amount under the revolving credit facility, and the maximum principal amount of the revolving credit facility was reduced from $20.0 million to $5.0 million. The new term loan is subject to substantially the same terms, including interest rate, amortization, and maturity date, as the prior term loan under the credit facility.

On July 30, 2021, the Company entered into a second amendment (the “2021 Amended Credit Agreement”) to the Existing Credit Agreement with Silicon Valley Bank, as agent and lender, MidCap Financial Trust, MidCap Funding XIII Trust, and the other lenders from time to time party thereto (collectively, the “Lenders”), providing for a term loan facility of up to $75.0 million, with $55.0 million available at closing and an additional $20.0 million (the “second tranche”) available upon positive Phase 1 clinical trial data in either of the Company’s two pipeline programs, FX201 and FX301, sufficient to initiate a Phase 2 clinical study, and a revolving credit facility of up to $25.0 million, both of which mature on February 1, 2024, which may be extended to July 1, 2026, upon satisfaction of certain specified conditions set forth in the 2021 Amended Credit Agreement (the “Maturity Date”). The Company concurrently borrowed the $55.0 million term loan (the “2021 term loan”), simultaneously used $48.1 million of the proceeds to repay the outstanding term loan under the Existing Credit Agreement, and drew down $20.0 million from the revolving

credit facility, bringing the total revolver balance to $25.0 million. In connection with the repayment of the Existing Credit Agreement, the Company recorded a debt extinguishment loss of $0.5 million primarily related to the write-off of the unamortized portion of the final payment, which was recorded as a component of interest expense on the statement of operations for the three and nine months ended September 30, 2021.

The Company granted the Lenders a security interest in substantially all of its personal property, rights, and assets, other than intellectual property, to secure the payment of all amounts owed under the ~~amended and restated credit and security agreement.~~2021 Amended Credit Agreement. The Company also agreed not to encumber any of its intellectual property without the Lenders’ prior written consent.

The ~~amended and restated credit and security agreement~~2021 Amended Credit Agreement contains certain representations, warranties, and covenants, ~~of the Company,~~ including a minimum revenue covenant that will be in effect at any time the Company’s liquidity (defined as cash, cash equivalents and marketable securities held with Silicon Valley Bank and certain accounts receivable as deemed eligible under the ~~amended and restated credit and security agreement)~~2021 Amended Credit Agreement) is below ~~$80.0 million.~~$100.0 million (if the second tranche is undrawn) or $120.0 million (if the second tranche is drawn). Additionally, if the Company’s liquidity is below ~~$80.0~~$100.0 million, all amounts received from customer collections will be applied immediately to reduce the revolving credit facility. ~~As filed in the Form 8-K issued by the Company on May 18, 2020, prior to May 2021, the~~The minimum revenue covenant, if it applies in the future, is ~~set annually~~applied to the trailing six-months of net revenue and is determined based on the ~~greater of (i) a conservative percentage of the year’s~~Company’s approved forecast, ~~and (ii) modest growth over~~as determined by the Lenders.

trailing twelve months of actual revenues. Beginning in May 2021, the minimum revenue covenant, if it applies, will be the greatest of (i) a conservative percentage of the year’s approved forecast, (ii) modest growth over the trailing twelve months of actual revenues and (iii) 100% of the minimum revenue covenant amount for the preceding month.

On May 18, 2020, the Company borrowed $15.0 million under a new term loan advance and immediately used the proceeds to repay an equal amount under the revolving credit facility, and the maximum principal amount of the revolving credit facility was reduced from $20.0 million to $5.0 million. The new term loan is subject to substantially the same terms, including interest rate, amortization and maturity date, as the existing term loan under the credit facility.

The amended and restated credit and security agreement also has a material adverse event clause. If the minimum revenue covenant becomes applicable and the Company fails to comply with it, or a material adverse change as defined in the agreement occurs, the amounts due under the amended and restated credit and security agreement could be declared immediately due and payable. As of ~~March 31,~~September 30, 2021, the Company was compliant with all financial covenants.

Term loan borrowings under the 2021 credit facility accrue interest monthly at a floating interest rate equal to the greater of ~~the~~(i) prime rate plus ~~1.5%~~2.75% or ~~6.5%~~(ii) 6.0% per ~~annum.~~annum. Following an interest-only period of 1824 months (if the second tranche is undrawn), or 36 months (if the second tranche is drawn), principal is due in 36 equal monthly installments ~~commencing February 1, 2021, and ending on the~~ through Maturity Date. Upon the Maturity Date, the Company will be obligated to pay a final payment equal to ~~6.75%~~4.75% of the total principal amounts borrowed under the facility. The final payment amount is being accreted to the carrying value of the debt using the straight-line method, which approximates the effective interest method. As of ~~March 31,~~September 30, 2021, the carrying value of the 2021 term loan was approximately ~~$53.1~~$55.1 million, all of which ~~$18.3 million~~ is ~~due within 12 months~~presented as long-term debt in the Company’s condensed consolidated balance sheet as of September 30, 2021. In connection with the planned merger with Pacira, the Company evaluated the terms of the 2021 Amended Credit Agreement and ~~$34.8 million is due in greater than 12 months.~~determined the agreement will require acceleration of payments upon a change of control.

The Company may prepay the term loan at any time by paying the outstanding principal balance, a final payment equal to ~~6.75%~~4.75% of the term loan amount, all accrued interest, and a prepayment fee of 3%3% of the outstanding term loan amount if repaid in the first year, 2%2% of the outstanding term loan amount if repaid in the second year, and 1%1% of the outstanding term loan amount if repaid in the third year of the loan; 0 prepayment fee is required thereafter.

As of ~~March 31,~~September 30, 2021, annual principal and interest payments due under the term loan were as follows:


Year	Aggregate Minimum Payments (in thousands)			Aggregate Minimum Payments (in thousands)
2021		16,026			568
2022		20,296			3,346
2023		19,088			10,907
2024		5,249			20,710
2025					19,587
Thereafter		—			13,523
Total	$	60,659		$	68,641
Less interest		(5,002	)		(11,029	)
Less unamortized portion of final payment		(2,566	)		(2,525	)
Total	$	53,091		$	55,087

Borrowings under the 2021 Amended Credit Agreement revolving credit facility accrue interest monthly at a floating interest rate equal to the greater of (i) the ~~prime rate~~Prime Rate plus 1.75% or ~~5.50% per annum.~~(ii) 5.00%. In addition to paying interest on any amounts borrowed under the revolving credit facility, the Company ~~owes~~may owe an unused revolving line facility fee equal to 0.25% per annum of the average unused portion of the revolving line, multiplied by the difference between the total amount available to be borrowed (the “Revolving Commitment Amount”) and the greater of the average outstanding revolver balance and 25% of the Revolving Commitment Amount. The revolving credit facility and any related fees or interest payments became available to the Company beginning January 1, 2020, and in February 2020, the Company drew down the $20.0 million available. On May 18, 2020, the Company repaid $15.0 million of the outstanding principal balance, and the maximum principal amount of the revolving credit facility was reduced from $20.0 million to $5.0 million.

Beginning on January 1, 2020, if the interest payment on the revolving credit facility is less than the amount of interest that would have been payable had the Company borrowed 25% of the Revolving Commitment Amount, then the Company will be required to pay the difference.

The Company may retire the revolving credit facility early, at any time, by paying the outstanding principal balance, all accrued interest, and a termination fee equal to 2%2% of the Revolving Commitment Amount if repaid in the first year, and 1%1% of the Revolving Commitment Amount if repaid in the second year; with 0 termination fee thereafter.

On May 2, 2017, the Company issued an aggregate of ~~$201.3~~$201.3 million principal amount of the 2024 Convertible Notes. The 2024 Convertible Notes have a maturity date of May 1, 2024, are unsecured, and accrue interest at a rate of ~~3.375%~~3.375% per annum, payable

semi-annually on May 1 and November 1 of each year, beginning November 1, 2017. The Company received ~~$194.8~~$194.8 million for the sale of the 2024 Convertible Notes, after deducting fees and expenses of ~~$6.5~~$6.5 million.

Upon conversion of the 2024 Convertible Notes, at the election of each holder of a 2024 Convertible Note (the ~~Holder)~~“Holder”), the note will be convertible into cash, shares of the Company’s common stock, or a combination thereof, at the Company’s election (subject to certain limitations in the 2015 term loan), at a conversion rate of approximately 37.3413 shares of common stock per ~~$1,000~~$1,000 principal amount of the 2024 Convertible Notes, which corresponds to an initial conversion price of approximately ~~$26.78~~$26.78 per share of the Company’s common stock.

The conversion rate is subject to adjustment from time to time upon the occurrence of certain events, including, but not limited to, fundamental change events and certain corporate events that occur prior to the maturity date of the notes. In addition, if the Company delivers a notice of redemption, the Company will increase, in certain circumstances, the conversion rate for a Holder who elects to convert its notes in connection with such a corporate event or notice of redemption, as the case may be. At any time prior to the close of business on the business day immediately preceding February 1, 2024, Holders may convert all, or any portion, of the 2024 Convertible Notes at their option only under the following circumstances:

On or after February 1, 2024, until the close of business on the business day immediately preceding the maturity date, Holders may convert their notes at any time, regardless of the foregoing circumstances. The Company may redeem, for cash, all or any portion of the 2024 Convertible Notes, at its option, on or after May 6, 2020, if the last reported sale price of the Company’s common stock has been at least ~~130%~~130% of the conversion price for at least 20 trading days during any 30 consecutive day trading period, at a redemption price equal to ~~100%~~100% of the principal amount of the 2024 Convertible Notes to be redeemed, plus accrued and unpaid interest, subject to the Holders’ right to convert as described above.

The 2024 Convertible Notes are considered convertible debt with a cash conversion feature. Per ASC 470-20, Debt with Conversion and Other Options,, the Company has separated the convertible debt into liability and equity components based on the fair value of a similar debt instrument excluding the embedded conversion option. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The allocation was performed in a manner that reflected our non-convertible debt borrowing rate for similar debt. The equity component of the 2024 Convertible Notes was recognized as a debt discount and represents the difference between the proceeds from the issuance of the 2024 Convertible Notes and the fair value of the liability of the 2024 Convertible Notes on their respective dates of issuance. The excess of the principal amount of the liability component over its carrying amount (“debt discount”) is amortized to interest expense using the effective interest method over seven ~~years.~~years. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The liability component of ~~$136.7~~$136.7 million was recorded as long-term debt at May 2, 2017, with the remaining equity component of ~~$64.5~~$64.5 million recorded as additional paid-in capital.

In connection with the issuance of the 2024 Convertible Notes, the Company incurred approximately ~~$6.5~~$6.5 million of debt issuance costs, which primarily consisted of underwriting, legal, and other professional fees, and allocated these costs to the liability and equity components based on the allocation of the proceeds. Of the total d~~ebt~~debt issuance costs, ~~$4.4~~$4.4 million was allocated to the liability component and are recorded as a reduction of the 2024 Convertible Notes in our consolidated balance sheets. The remaining ~~$2.1~~$2.1 million was allocated to the equity component and is recorded as a reduction to additional paid-in capital.

Debt discount and issuance costs of $68.9 ~~costs~~million are being amortized to interest expense over the life of ~~$68.9 millionarebeingamortized~~to~~interestexpenseover~~the~~life~~of~~the~~2024ConvertibleNotesusing theeffectiveinterest rate method.Asof ~~March 31,~~September 30, 2021,thestatedinterestrate was3.375~~3.375%~~%, and the effective interest rate was 9.71~~andtheeffectiveinterestratewas9.71%~~%.Interestexpenserelatedtothe 2024ConvertibleNotesforthe three and nine months ended ~~March 31,~~September 30, 2021, was ~~$4.0~~$4.1 million and $, 12.2~~including~~ ~~$2.3~~ million, including $2.4 million and $7.2 million, related to amortization of the debt discount.

~~amortization~~of~~thedebtdiscount.~~

The table below summarizes the carrying value of the 2024 Convertible Notes as of ~~March 31,~~September 30, 2021:


	(in thousands)
Gross proceeds	$	201,250
Portion of proceeds allocated to equity component (additional paid-in capital)		(64,541	)
Debt issuance costs		(6,470	)
Portion of issuance costs allocated to equity component (additional paid-in capital)		2,075
Amortization of debt discount and debt issuance costs		38,104
Carrying value 2024 Convertible Notes	$	170,418

The fair value of each of the Company’s stock option grants is estimated on the date of grant using the Black-Scholes option-pricing model. Expected volatility is based on historical volatility of the Company’s common stock. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain vanilla” options. The expected term of stock options granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. The relevant data used to determine the value of the stock option grants for the three and nine months ended ~~March 31,~~September 30, 2021 and 2020, were as follows:

The following table summarizes stock option activity for the ~~three~~nine months ended ~~March 31,~~September 30, 2021:


(In thousands, except per share amounts)	Shares Issuable Under Options			Weighted Average Exercise Price Per Share		Shares Issuable Under Options			Weighted Average Exercise Price Per Share
Outstanding as of December 31, 2020		4,592		$	17.77		4,592		$	17.77
Granted		120			11.41		587			8.30
Exercised		(43	)		3.40		(43	)		3.40
Cancelled		(56	)		19.81		(837	)		18.81
Outstanding as of March 31, 2021		4,613		$	17.71
Options vested and expected to vest at March 31, 2021		4,613		$	17.71
Options exercisable at March 31, 2021		3,661		$	18.23
Outstanding as of September 30, 2021							4,299		$	16.42
Options vested and expected to vest at September 30, 2021							4,299		$	16.42
Options exercisable at September 30, 2021							3,302		$	17.91

The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company’s common stock for those options that had exercise prices lower than the fair value of the Company’s common stock. Options to purchase a total of 42,682 shares of the Company’s common stock, with an aggregate intrinsic value of approximately ~~$386,138,~~$386,138, were exercised during the ~~three~~nine months ended ~~March 31,~~September 30, 2021.

At ~~March 31,~~September 30, 2021 and 2020, there were options for the purchase of ~~4,613,050~~4,299,337 and ~~4,934,879~~4,753,623 shares of the Company’s common stock outstanding, respectively, with a weighted average remaining contractual term of ~~5.9~~6.0 years and ~~6.9~~6.5 years, respectively, and with a weighted average exercise price of ~~$17.71~~$16.42 and ~~$17.92~~$17.74 per share, respectively.

The weighted average grant date fair value of options granted during the ~~three~~nine months ended ~~March 31,~~September 30, 2021 and 2020, was ~~$7.27~~$5.28 and ~~$9.63~~$8.86 per share, respectively.

During the ~~three~~nine months ended ~~March 31,~~September 30, 2021, the Company awarded ~~944,715~~1,169,320 restricted stock units (“RSUs”) to employees at a weighted average grant date fair value of ~~$9.89~~$10.79 per share. The majority of the RSUs vest in ~~four~~4 substantially equal installments on each of the first 4four anniversaries of the vesting commencement date, subject to the employee’s continued employment with, or services to, the Company on each vesting ~~date.~~date. Compensation expense is recognized on a straight-line basis.

Included in the 2021 RSU awards was a grant of 106,100 RSUs to the Company’s chief executive officer. These RSUs have two performance conditions relating to achieving a certain revenue threshold for the year ending December 31, 2021, as well as progressing at least one of the Company’s current pipeline assets. The number of shares ultimately eligible for vesting under the RSU award will depend upon the degree to which the performance conditions are achieved. The maximum number of shares that are eligible for vesting under the award is 159,150, which would be earned based on ~~150%~~150% achievement of the performance conditions. The portion of the RSUs eligible for vesting will vest in four substantially equal installments starting in 2022 upon confirmation of such performance metrics being achieved and thereafter on January 1 of the subsequent three years so that all of such shares will have vested on January 1, 2025, subject to the employee’s continued employment with, or services to, the Company on each vesting date. As of ~~March 31,~~September 30, 2021, the Company concluded that it was not probable that either performance condition would be met. Therefore, 0 expense has been recognized on these awards during the three and nine months ended ~~March 31,~~September 30, 2021.

The following table summarizes the RSU activity for the ~~three~~nine months ended ~~March 31,~~September 30, 2021:


(In thousands, except per share amounts)	Number of Shares			Weighted Average Grant Date Fair Value Per Share		Number of Shares			Weighted Average Grant Date Fair Value Per Share
Nonvested balance as of December 31, 2020		2,193		$	14.15		2,193		$	14.15
Granted		945			9.89		1,169			10.79
Vested/Released		(373	)		15.33		(626	)		14.57
Cancelled		(79	)		13.51		(490	)		13.42
Nonvested Balance as of March 31, 2021		2,686		$	12.51
Nonvested Balance as of September 30, 2021							2,246		$	12.45

The Company recorded stock-based compensation expense related to stock options and RSUs and shares purchased under the Employee Stock Purchase Plan for the three and nine months ended ~~March 31,~~September 30, 2021 and 2020, as follows:


	For the three months ended March 31,				For the three months ended September 30,				For the nine months ended September 30,
(In thousands)	2021		2020		2021		2020		2021		2020
Research and development	$	1,279	$	2,202	$	1,166	$	1,403	$	3,469	$	4,692
Selling, general and administrative		3,361		2,449		3,030		3,556		9,342		8,705
Total	$	4,640	$	4,651	$	4,196	$	4,959	$	12,811	$	13,397

As of ~~March 31,~~September 30, 2021, unrecognized stock-based compensation expense for stock options outstanding was approximately ~~$9.0~~$6.7 million, which is expected to be recognized over a weighted average period of ~~2.1~~2.5 years. As of ~~March 31,~~September 30, 2021, unrecognized stock-based compensation expense for RSUs outstanding was ~~$29.0~~$21.9 million, which is expected to be recognized over a weighted average period of ~~2.6~~2.3 years.

11. Net Loss per Share

~~11.~~

~~Net Loss per Share~~

Basic and diluted net loss per share attributable to common stockholders was calculated as follows for the three and nine months ended ~~March 31,~~September 30, 2021 and 2020:

The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated as including them would have an anti-dilutive effect:


	For the three months ended September 30,				For the nine months ended September 30,
(In thousands)	2021		2020		2021		2020
Shares issuable upon conversion of the 2024 Convertible Notes		7,515		7,515		7,515		7,515
Stock options		4,676		4,986		4,579		4,946
Restricted stock units		2,301		2,058		2,350		1,485
Total		14,492		14,559		14,444		13,946

For the three months
ended March 31,

(In thousands)

2021

2020

Shares issuable upon conversion of the
2024 Convertible Notes

7,515

7,515

Stock options

4,660

4,864

Restricted stock units

2,153

912

Total

14,328

13,291

In May 2013, the Company entered into a lease for office space in Burlington, Massachusetts (the “Lease”), for an initial term of 42 months. In June 2019, the Company amended the Lease to add additional square feet of office space and extend the term of the Lease through April 30, 2025 (the “Amended Lease”). As a result of the Amended Lease, the total rentable floor area is 41,873 square feet. Starting in August 2019, the Company’s minimum monthly lease payment is approximately ~~$108,000,~~$108,000, which increases over the term of the Amended Lease. In addition to the base rent for the office space, the Company is responsible for its share of operating expenses and real estate taxes.

The ~~straight-line~~ lease cost for the Amended Lease (including the expense relating to the original Lease) ~~amounted to $0.5 million~~ for the three and nine months ended ~~March 31,~~September 30, 2021, amounted to $0.5 million and $1.4 million for each of the three and nine months ended September 30, 2021 and 2020, respectively, and was included in operating expenses. As of ~~March 31,~~September 30, 2021, the remaining lease term on the Amended Lease was ~~4.1~~3.6 years, which includes the ~~18-month~~18-month extension resulting from the amendment signed in June 2019.

In February 2017, the Company entered into a five-year lease for laboratory space located in Woburn, Massachusetts, with a monthly lease payment of approximately ~~$15,000,~~$15,000, which increases over the term of the lease, plus a share of operating expenses. The ~~straight-line~~ lease cost for the Woburn lease amounted to ~~$46,000~~$58,000 and $150,000 for the three and nine months ended ~~March 31,~~September 30, 2021 respectively, as compared to $46,000and ~~2020,~~$139,000, respectively, for the same periods in the prior year, and was included in operating expenses.

In June 2021, the Company amended the Woburn lease to extend the term of the lease through February 29, 2024. Starting in March 2022, the Company’s minimum monthly lease payment will be approximately $20,400, which increases over the term of the amended lease. The Company accounted for the amended lease as a modification that is not a separate contract from the original lease, as the amended lease does not contain any additional rights, and recorded an incremental right-of-use asset and lease liability of $0.4 million, which represents the present value of the lease payments over the remaining lease term of 2.7 years, discounted at 8.4%. As of ~~March 31,~~September 30, 2021, the remaining lease term on the Woburn lease, as amended, was ~~11 months.~~2.4 years.

In July 2015, the Company and Patheon UK Limited (“Patheon”) entered into a Manufacturing and Supply Agreement (the “Manufacturing Agreement”) and a Technical Transfer and Service Agreement (the “Technical Transfer Agreement”) for the manufacture of ZILRETTA.

Patheon agreed in the Technical Transfer Agreement to undertake certain transfer activities and construction services needed to prepare Patheon’s United Kingdom facility for the commercial manufacture of ZILRETTA in dedicated manufacturing suites. The Company provided Patheon with certain equipment and materials necessary to manufacture ZILRETTA and pays Patheon a monthly fee for such activities and reimburses Patheon for certain material, equipment, and miscellaneous expenses and additional services.

The initial term of the Manufacturing Agreement is 10 years from approval by the FDA of the Patheon manufacturing suites for ZILRETTA, or until October 6, 2027. The Company pays a monthly base fee to Patheon for the operation of the manufacturing suites and a per product fee for each vial based upon a forecast of commercial demand. The Company also reimburses Patheon for purchases of materials and equipment made on its behalf, certain nominal expenses, and additional services. The Manufacturing Agreement will remain in full effect unless and until it expires or is terminated. Upon termination of the Manufacturing Agreement (other than termination by Flexion in the event that Patheon does not meet the construction and manufacturing milestones or for a breach by Patheon), Flexion will be obligated to pay for the costs incurred by Patheon associated with the removal of Flexion’s manufacturing equipment and for Patheon’s termination costs up to a capped amount.

The Manufacturing Agreement with Patheon contains an operating lease for the use of dedicated manufacturing suites. With the adoption of ASU 2016-02, the Company recorded a right-of-use asset and corresponding lease liability for the operating lease.

In June 2019, the Company and Patheon amended the Manufacturing Agreement and the Technical Transfer Agreement. The amendment primarily modifies the compensation structure, which is comprised of base fees and per product fees the Company pays to Patheon and does not result in any additional rights of use. The Company accounted for the amendment as a lease modification that is not a separate contract from the original lease. As part of the modification, the Company reassessed whether the contract is or contains a lease and determined that there is an operating lease component for the use of dedicated manufacturing suites. The remainder of the consideration is allocated to the service component. The Company also reassessed the lease liability by calculating the present value of

the remaining lease payments as of the modification date, discounted at ~~6.1%~~6.1%. The modification resulted in an increase to each of the lease liability and right of use asset of ~~$0.5~~$0.5 million.

In April 2020, the Company entered into a side letter amending the Manufacturing Agreement with Patheon pursuant to which the parties agreed that the Company would continue to pay the monthly base fee for maintaining the manufacturing suites, but minimum purchase obligations would be cancelled for 2020 as the Company temporarily suspended manufacturing activities for ~~ZILRETTA.~~ZILRETTA due to COVID-19. The amendment did not change the amount of fixed consideration owed to Patheon over the life of the contract, nor did it grant the Company any additional rights of use. As such, there was no change in the accounting for the embedded lease as a result of this amendment. The Company restarted manufacturing activities at Patheon in the fourth quarter of 2020.

As of ~~March 31,~~September 30, 2021, the remaining lease term on the Patheon lease was ~~6.6~~6.1 years. The ~~straight-line~~ lease cost for the three and nine months ended September 30, 2021, amounted to ~~$62,000,~~$61,000 and $185,000, respectively, compared to $58,000 and $171,000, respectively, for the ~~three months ended March 31, 2021, respectively,~~same periods in the prior year, and is included in inventory as part of manufacturing overhead.

(In thousands)

For the three months
ended March 31,

Operating lease cost

2021

2020

Operating lease cost included in operating expenses

$
513

$
513

Operating lease cost included in inventory

62

57

Total operating lease cost

575

570

Operating cash flows from operating leases

786

818

Maturities of lease liability due under these lease agreements as of ~~March 31,~~September 30, 2021, were as follows:

In November 2016, the Company entered into a Supply Agreement with Evonik Corporation (“Evonik”) for the purchase of PLGA, which is used in the manufacturing of clinical and commercial supply of ZILRETTA. Pursuant to the Supply Agreement, Flexion is obligated to submit rolling monthly forecasts to Evonik for PLGA supply, a portion of which will constitute binding orders. In addition, Flexion agreed to certain minimum purchase requirements, which do not apply (i) during periods in which Evonik is in material breach of the Supply Agreement or is unable to perform its obligations due to a force majeure event, (ii) with respect to orders that Evonik is unable to supply in excess of binding orders, (iii) for orders Evonik is unable to timely deliver or does not deliver conforming product and provides a credit for such order, or (iv) during an uncured material quality failure by Evonik. Flexion agreed to purchase PLGA batches at a specified price per gram in U.S. dollars, subject to adjustment from time to time, including due to changes in price indices and in the event the initial term of the Supply Agreement was extended. The initial term of the agreement was five years, commencing in July 2016. In May 2021, the Company entered into an amendment to the Supply Agreement that ~~will be~~became effective on June 30, 2021. The total term of the Supply Agreement, as amended, is eight years. Upon termination of the Supply Agreement (other than termination due to the bankruptcy of either Evonik or Flexion), Flexion is obligated to pay the costs associated with the binding supply forecast provided to Evonik.

In December 2017, the Company entered into a definitive agreement with GeneQuine Biotherapeutics GmbH (“GeneQuine”) to acquire the global rights to FX201. As part of the asset purchase transaction, ~~with GeneQuine,~~ the Company made an upfront payment to GeneQuine of $2.0 million. The upfront fee was attributed to the intellectual property acquired and recognized as research and development expense in December 2017 as the FX201 rights had not been commercially approved and had no alternative future use. In 2018, the Company paid GeneQuine ~~$750,000~~$750,000 for initiating a GLP toxicology study of FX201. In addition, the Company paid GeneQuine ~~$750,000~~$750,000 in November 2019 following the FDA acceptance of the ~~IND~~Investigational New Drug (“IND”) application for FX201. The next milestone of ~~$2.5~~$2.5 million was achieved in March 2020, when the first patient was treated in the Phase 1 clinical trial. The Company may also be required to make additional milestone payments during the development of FX201, including up to ~~$4.5~~$4.5 million for the initiation of a Phase 2 proof of concept ~~(PoC),~~(“PoC”) clinical trial and, following successful PoC, up to an additional $51.5 million in development and global regulatory approval milestone payments. The transaction was accounted for as an asset acquisition, as it did not qualify as a business combination. Milestone payments earned prior to regulatory approval of FX201 are recognized as research and development expense in the period when the milestone events become probable of being achieved. Future milestones earned upon regulatory approval would be recognized as an intangible asset and amortized to expense over its estimated life. As of ~~March 31,~~September 30, 2021, 0 other milestones under the arrangement were probable of being achieved. As part of the transaction, the Company became the direct licensee of certain underlying Baylor College of Medicine ~~(Baylor)~~(“Baylor”) patents and other proprietary rights related to FX201 for human applications. The Baylor license agreement grants the Company an exclusive, royalty-bearing, world-wide right and license (with a right to sublicense) for human applications under its patent and other proprietary rights directly related to FX201, with a similar non-exclusive license to certain Baylor intellectual property rights that are not specific to FX201. The license agreement with Baylor includes a low single-digit royalty on net sales of FX201 and requires the Company to use reasonable efforts to develop FX201 according to timelines set out in the license agreement. In December 2017, the Company also entered into a Master Production Services Agreement with SAFC Carlsbad, Inc., a part of MilliporeSigma, for the manufacturing of preclinical and initial clinical supplies of FX201. In addition, in February 2020 the Company entered into a manufacturing agreement with another vendor for clinical trial supply of FX201 through Phase 3 clinical trials.

In September 2019, the Company entered into a definitive agreement with Xenon Pharmaceuticals, Inc. (“Xenon”) that provides the Company with the global rights to develop and commercialize XEN402, Xenon’s NaV1.7 inhibitor known as funapide, formulated for extended release with a novel, Flexion proprietary thermosensitive hydrogel under the Company’s preclinical program known as FX301. The transaction was accounted for as an asset acquisition, as it did not qualify as a business combination. As part of the asset purchase transaction, ~~with Xenon,~~ the Company made an upfront payment to Xenon of ~~$3.0~~$3.0 million. The upfront fee was attributed to the intellectual property acquired and was recognized as research and development expense in September 2019 as the FX301 product candidate had not been commercially approved and had no alternative future use. The next milestone of ~~$0.5~~$0.5 million was achieved following the commencement of the GLP toxicology study. This milestone was recognized as research and development expense in the first quarter of 2020. ~~Two milestones were achieved in~~The Company also paid $1.0 million when the ~~first quarter of 2021, including $1.0 million earned upon the clearing of the~~ IND was cleared by FDA in February 2021 and ~~$2.0~~$2.0 million ~~earned~~ upon the initiation of the Phase 1b clinical ~~trial.~~trial in March 2021. These milestones were recognized as research and development expenses in the first quarter of 2021. The Company may also be required to make additional milestone payments during the development of FX301, including up to ~~$5.0~~$5.0 million through initiation of a Phase 2 PoC clinical trial and, following successful PoC, up to ~~$40.8~~$40.8 million in development and global regulatory approval milestone payments and up to an additional ~~$75.0~~$75.0 million in sales-related milestone payments. Future milestone payments earned prior to regulatory approval of FX301 would be recognized as research and development expense in the period when the milestone events become probable of being achieved. Future milestones earned subsequent to regulatory approval would be recognized as an intangible asset and amortized to expense over the estimated life of FX301. As of ~~March 31,~~September 30, 2021, 0 other milestones under the arrangement were probable of being achieved. As part of the transaction, the Company became the direct licensee of certain underlying Xenon patents and other proprietary rights related to XEN402 for human applications. The Xenon agreement grants the Company an exclusive, royalty-bearing, world-wide right and license (with a right to sublicense) for human applications under its patents directly related to XEN402, with a similar royalty-free license to other Xenon proprietary rights directly related to XEN402. The agreement with Xenon includes a tiered royalty ranging from mid-single digits to low double digits that is based on aggregate annual net sales of FX301 and requires the Company to use reasonable efforts to develop FX301 according to timelines set out in the agreement.

Between October 22, 2021, and November 10, 2021, eleven complaints were filed in federal court by purported stockholders of Flexion regarding the Merger. The first complaint was filed on October 22, 2021, in the United States District Court for the Southern District of New York and is captioned Elaine Wang v. Flexion Therapeutics, Inc., et al., Case No. 1:21-cv-08693. The second complaint was filed on October 28, 2021, in the United States District Court for the Southern District of New York and is captioned Marc Waterman v. Flexion Therapeutics, Inc., et al., Case No. 1:21-cv-08804 (S.D.N.Y filed October 28, 2021). The third complaint was filed on October 28, 2021, in the United States District Court for the Southern District of New York and is captioned Melinda Turkington v. Flexion Therapeutics, Inc., et al., Case No. 1:21-cv-08817. The fourth complaint was filed on November 1, 2021, in the United States District Court for the Southern District of New York and is captioned Barbara Hart v. Flexion Therapeutics, Inc., et al., Case No. 1:21-cv-08919. The fifth complaint was filed on November 1, 2021, in the United States District Court for the Southern

District of New York and is captioned Lee Beary v. Flexion Therapeutics, Inc., et al., Case No. 1:21-cv-08925. The sixth complaint was filed on November 2, 2021, in the United States District Court for the Southern District of New York and is captioned Katherine Finger v. Flexion Therapeutics, Inc., et al., Case No. 1:21-cv-09032. The seventh complaint was filed on November 2, 2021, in the United States District Court for the Eastern District of New York and is captioned David Gruver v. Flexion Therapeutics, Inc., et al., Case No. 1:21-cv-06106. The eighth complaint was filed on November 3, 2021, in the United States District Court for the Southern District of New York and is captioned Theodore Meshover v. Flexion Therapeutics, Inc., et al., Case No. 1:21-cv-09043. The ninth complaint was filed on November 4, 2021, in the United States District Court for the District of Delaware and is captioned Sam Carlisle v. Flexion Therapeutics, Inc., et al., Case No. 1:21-cv-01572-UNA. The tenth complaint was filed on November 4, 2021, in the United States District Court for the Eastern District of Pennsylvania and is captioned Alex Ciccotelli v. Flexion Therapeutics, Inc., et al., Case No. 2:21-cv-04885. The eleventh complaint was filed on November 10, 2021, in the United States District Court for the District of Delaware and is captioned James Murray v. Flexion Therapeutics, Inc., et al., Case No. 1:21-cv-01590-UNA(collectively, the “Complaints”). The Complaints name as defendants Flexion and each member of Flexion’s board of directors (the “Flexion Defendants”). The Waterman complaint additionally names as defendants Pacira and Purchaser (the “Pacira Defendants”). The plaintiffs generally contend that the Solicitation/Recommendation Statement on Schedule 14D-9, filed on October 22, 2021, has omitted or misrepresented material information regarding the Merger. The Hart complaint additionally alleges that Flexion engaged in an insufficient sales process and that members of Flexion’s board of directors and Flexion’s management had conflicts of interest with Flexion’s stockholders. The Complaints allege violations of Section 14(d) and/or Section 14(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) against all Flexion Defendants and assert violations of Section 20(a) of the Exchange Act against the members of Flexion’s board of directors. The Waterman complaint additionally alleges violations of Section 14(d), Section 14(e), and Section 20(a) of the Exchange Act against the Pacira Defendants. The Complaints collectively seek, among other relief, (i) injunctive relief preventing the consummation of the transactions contemplated by the Merger Agreement; (ii) rescission and/or rescissory damages in the event the transactions contemplated by the Merger Agreement are consummated; (iii) other damages purportedly incurred on account of defendants’ alleged misstatements or omissions; (iv) disclosure of certain information requested by the plaintiffs; (v) declaratory relief stating defendants violated the Exchange Act; and (vi) an award of plaintiffs’ expenses and attorneys’ fees. The Flexion Defendants have been served with the Wang complaint and the Hart complaint, but have not been served with any of the other Complaints.On November 12, 2021, the Company filed a Schedule 14D-9/A containing certain supplemental disclosures in order to moot the claims alleged in the Complaints. The Flexion Defendants’ deadline to respond to the Wang complaint is December 27, 2021, and the Flexion Defendants’ deadline to respond to the Hart complaint is January 3, 2022.

Each of the Flexion Defendants and the Pacira Defendants intend to vigorously defend these actions. The Company believes that the Complaints are without merit and has not recorded an expense related to the outcome of these litigations because it is not yet possible to determine if a potential loss is probable nor reasonably estimable.

At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to its legal proceedings.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and the financial statements and accompanying notes thereto for the fiscal year ended December 31, 2020, and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K filed by us with the Securities and Exchange Commission, or SEC, on March 10, 2021.

This discussion and analysis contains “forward-looking statements” ~~that is~~—as defined in Section 21E of the Exchange Act—which are statements related to future, not past, events ~~– as defined in Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act that~~and reflect our current expectations regarding future development activities, results of operations, financial condition, cash flow, performance, and business prospects and opportunities, as well as assumptions made by and information currently available to our management. Forward-looking statements include any statement that does not directly relate to a current historical fact. We have tried to identify forward-looking statements by using words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “predict,” “potential,” “believe,” ~~“should”~~“should,” and similar expressions. Although we believe that the expectations reflected in these forward-looking statements are reasonable,

we cannot guarantee future results, events, levels of activity, performance, or achievement. We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this report or to reflect actual outcomes. The forward-looking statements in this Quarterly Report on Form 10-Q, other than the statements regarding the proposed acquisition by Pacira BioSciences, Inc. (“Pacira”), do not assume the consummation of the proposed acquisition unless specifically stated otherwise.

~~Overview~~Forward-looking statements include, without limitation, statements regarding the anticipated consummation and timing of the acquisition of Flexion by Pacira and payments that may be made upon the satisfaction of specified milestones, which are each based

on Pacira’s and Flexion’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Pacira’s ability to complete the transaction on the proposed terms and schedule or at all; whether the tender offer conditions will be satisfied; whether sufficient stockholders of Flexion tender their shares in the transaction; the outcome of legal proceedings instituted against Flexion and/or others relating to the transaction; the failure (or delay) to receive the required regulatory approvals relating to the transaction; the possibility that competing offers will be made; risks related to future opportunities and plans for Flexion and its products, including uncertainty of the expected financial performance of Flexion and its products, including whether the milestones will ever be achieved; and the occurrence of any event, change, or other circumstance that could give rise to the termination of the acquisition agreement, as well as other risks related to Pacira’s and Flexion’s businesses detailed from time-to-time under the caption “Risk Factors” and elsewhere in Pacira’s and Flexion’s respective SEC filings and reports, including their respective Annual Reports on Form 10-K for the year ended December 31, 2020, and subsequent quarterly and current reports filed with the SEC.

We are a biopharmaceutical company focused on the discovery, development, and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis, referred to as OA.

On October 6, 2017, the U.S. Food and Drug Administration ~~(FDA)~~(“FDA”), approved our product, ZILRETTA, for marketing in the United States. ZILRETTA is the first and only extended-release, intra-articular, or IA (meaning in the joint), injection indicated for the management of OA related knee pain. ZILRETTA is a non-opioid therapy that employs our proprietary microsphere technology to provide pain relief. The pivotal Phase 3 trial, on which the approval of ZILRETTA was based, showed that ZILRETTA met the primary endpoint of pain reduction at Week 12, with statistically significant pain relief extending through Week 16.

We also have two pipeline programs focused on the local treatment of musculoskeletal conditions: FX201, which is an investigational IA gene therapy product candidate in clinical development for the treatment of OA, and FX301, an investigational NaV1.7 inhibitor product candidate in clinical development as a locally administered peripheral analgesic nerve block for control of post-operative pain.

We were incorporated in Delaware in November 2007, and, to date, we have devoted substantially all of our resources to developing our product candidates, including conducting clinical trials with our product candidates, preparing for and undertaking the commercialization of ZILRETTA, providing general and administrative support for these operations, and protecting our intellectual property. From our inception through ~~March 31,~~September 30, 2021, we have funded our operations primarily through the sale of our common stock, convertible preferred stock, and convertible debt, as well as debt financing. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, government or third-party funding, and licensing or collaboration arrangements.

On ~~November 4, 2020,~~October 11, 2021, we entered into an ~~Equity Distribution~~ Agreement and Plan of Merger (the ~~“Distribution~~“Merger Agreement”) with ~~Goldman Sachs & Co. LLC~~Pacira and ~~Credit Suisse Securities (USA) LLC (collectively, the “Managers”~~Oyster Acquisition Company Inc., a Delaware corporation and wholly owned subsidiary of Pacira (“Purchaser”) ~~relating~~. Pursuant to the ~~issuance~~Merger Agreement, on October 22, 2021, Purchaser commenced a tender offer (the “Offer”) to purchase each issued and ~~sale from time~~outstanding share of our common stock (the “Shares”) at an offer price of (i) $8.50 per Share in cash, net of applicable withholding taxes and without interest, plus (ii) one non-transferable contractual contingent value right per Share, which will represent the right to ~~time of~~receive one or more contingent payments up to ~~$100,000,000~~$8.00 in the aggregate, in cash, net of ~~shares~~applicable withholding taxes and without interest, upon the achievement of specified milestones on or prior to December 31, 2030.

Promptly following the completion of the Offer, upon the terms and subject to the conditions of the Merger Agreement, Purchaser will merge with and into Flexion (the “Merger”), with Flexion continuing as the surviving corporation and as a wholly owned subsidiary of Pacira. The Merger Agreement contemplates that the Merger will be effected pursuant to Section 251(h) of the Delaware General Corporation Law, which permits completion of the Merger without a vote of the holders of our common stock upon the acquisition by Purchaser of a majority of the aggregate voting power of our common stock. ~~Under the terms~~As a result of the ~~Distribution Agreement,~~Merger, we will ~~pay the Managers~~cease to be a ~~commission of up~~publicly traded company.

The Merger Agreement contains customary representations and warranties. The Merger is expected to ~~3% of the gross sales price of any shares sold. As of March 31, 2021, 134,048 shares have been sold under the Distribution Agreement, for total net proceeds of $1.7 million.~~

In December 2019, a novel strain of coronavirus, which causes the COVID-19 disease, was first reported in Wuhan, China and has since become a global pandemic (“COVID-19”). COVID-19 has presented a substantial public health and economic challenge around the world and has affected our employees, patients, communities and business operations, as well as the U.S. economy and financial markets. COVID-19 continues to affect patient flows to healthcare providers, and we expect visits to orthopedic practices will remain at approximately 80% of their pre-COVID levels through at least the middle of this year.

With respect to the rollout of the COVID-19 vaccines, despite the absence of guidance from the Centers for Disease Control and Prevention (CDC), out of an abundance of caution, some physicians opted to defer IA steroid injections for a period of two weeks prior to COVID-19 vaccination through two weeks post completion of the vaccination regimen. ZILRETTA's market largely consists of Medicare age patients and seniors who were prioritized for COVID vaccinations throughout the first quarter of 2021. Atclose before the end of ~~February,~~the calendar year 2021, subject to the satisfaction or waiver of customary closing conditions, including, among others, that the number of Shares tendered in the Offer represent at least one Share more than 50% of the total number of Shares at the time of the expiration of the Offer. The Merger Agreement provides Pacira and Flexion with certain termination rights and, under certain circumstances, may require us to pay Pacira a termination fee of $18.0 million.

For additional information related to the Merger Agreement, refer to the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company filed with the SEC on October 22, 2021, together with the exhibits and annexes thereto and as amended or supplemented from time to time. Please also see “Item 1A. Risk Factors—Risks Related to Our Pending Acquisition by Pacira.

ZILRETTA net sales in the third quarter were $21.3 million. We believe that our commercial performance reflects the adverse impacts of several key factors.

First, in August, we ~~conducted~~introduced a ~~spot survey~~ZILRETTA price increase coupled with an “off-invoice discount” (OID) program intended to mitigate the impacts of ~~30 physicians and orthopedic practices and approximately 30%~~the increase. As part of ~~respondents indicated their steroid administrations~~this program, providers have the ability to earn higher discounts in exchange for purchasing more units in each order. In conjunction with those changes, we revised the discount tiers such that the discounts offered at the lowest purchasing tiers were ~~between 20% and 50% lower~~less than they were prior to the ~~availability~~implementation of the ~~COVID-19 vaccines. As of April 5,~~OID program. Our goal was to incentivize higher purchasing volumes by healthcare practices; however, some accounts were reluctant to increase order sizes in amounts sufficient to obtain the ~~CDC reported that nearly 60% of all people aged 65 and older had been fully vaccinated, and we~~more favorable cost recovery available in the higher discount tiers. We believe that this program had the ~~impacts from~~unanticipated effect of causing accounts to purchase less product than we had forecast.

Second, COVID-19 ~~vaccinations on steroid injections will become less meaningful~~and the emergence of the Delta variant resulted in reduced patient flows and restricted our Musculoskeletal Business Managers’ (MBMs) ability to access key office personnel. These restrictions were particularly acute in August and September as COVID cases spiked in a number of key regions.

~~In spite of these challenges,~~quarter were reduced due to several unanticipated manufacturing batch failures in late 2020 and in the first ~~quarter~~half of 2021 ~~we saw~~that contributed to short-dated ZILRETTA units purchased by health care providers grow by 6% over the fourth quarter of 2020. We believe that as more clinicians and patients gain more experience with ZILRETTA, it can become a leading treatment option for patients with OA knee pain. While we are encouraged by the growth of ZILRETTA purchases by healthcare providers we sawinventory in the ~~first quarter~~distribution channel, resulting in smaller order sizes by physician practices and product returns from specialty distributors. The product returns were a consequence of ~~2021,~~ the ~~future impact of COVID-19 on~~drop in demand during the quarter. If demand had been in line with our ~~business remains uncertain~~forecast, significantly more inventory would have been consumed, and ~~unpredictable.~~

~~In May 2021,~~ we ~~introduced updated commercial metrics~~anticipate that we would have avoided having short-dated product in the channel. We adjusted our manufacturing process to ~~provide increased visibility~~address the batch failures, and ~~insights~~subsequent batches have fully met our product specifications and have been entered into the ~~commercial performance~~supply chain. These new batches have greater than 12 months of ~~ZILRETTA. In~~expiry remaining, which is consistent with the ~~first quarter of 2021:~~product dating that we were selling prior to the pause in manufacturing due to COVID-19.

ZILRETTA/FX006 (triamcinolone acetonide extended-release injectable suspension) - IA treatment for OA

ZILRETTA is the first and only extended-release IA therapy for patients confronting OA-related knee ~~pain, and~~pain. In September 2021, we announced the inclusion of ZILRETTA in the American Academy of Orthopaedic Surgeons (AAOS) updated evidence-based clinical practice guidelines for the management of OA of the knee. The AAOS guidelines reflect a moderate recommendation for the use of intra-articular (IA) corticosteroids for patients with symptomatic OA of the knee. The recommendation follows a review of data from 25 studies assessing IA corticosteroids. Included in its rationale is a differential analysis of extended-release intra-articular steroid, of which ZILRETTA is the only available product, versus immediate-release IA corticosteroids, where AAOS analyses demonstrated that it can, “be used over immediate-release corticosteroids to improve patient outcomes.”

In addition to knee OA, we believe that ZILRETTA’s extended-release profile may also provide effective treatment for OA pain in other large joints, including the ~~shoulder. We intend~~shoulder and in August results from the Phase 2 pharmacokinetic (“PK”) trial assessing the safety and general tolerability of ZILRETTA in OA of the shoulder were published in Drugs in R&D. PK and safety profiles of ZILRETTA were similar to those reported in Phase 3 studies of patients with knee OA. Plasma PK findings from this study were also consistent with the extended release of triamcinolone acetonide (“TA”) within the synovial fluid following an IA injection of ZILRETTA in the knee. Plasma PK data indicate the total and maximal exposure to TA was approximately two-thirds lower in patients treated with ZILRETTA compared to triamcinolone acetonide in crystalline suspension. With respect to our plans to initiate a registration ~~trial investigating ZILRETTA~~study in shoulder OA by end of year, based on recent interactions with FDA, we are currently reassessing the proposed study design and determining the best path forward given FDA’s feedback.

At the American College of Rheumatology (ACR) annual meeting in ~~2021.~~November we presented data from our open-label Phase 3b trial assessing the effect of a single administration of ZILRETTA on synovitis in 129 patients with knee OA. In patients with knee OA and baseline synovitis (n=102), ZILRETTA significantly reduced synovial tissue volume at Week 6 (primary endpoint). These patients also reported improvements in WOMAC-A (pain), B (stiffness), and C (function) and KOOS-QoL scores through Week 24. ZILRETTA was well tolerated and there were no new or unexpected adverse events.

FX201 (humantakinogene hadenovec) – Locally Administered Gene Therapy for the Treatment of OA

FX201 is our novel, clinical stage, investigational IA gene therapy product candidate, which is designed to induce the production of interleukin-1 receptor antagonist ~~(IL-1Ra)~~(“IL-1Ra”), an anti-inflammatory protein. Preclinical data suggest that, following injection of FX201, its genetic material is incorporated into local cells and IL-1Ra is expressed in response to inflammation in the joint tissues. Inflammation is a known cause of pain, and chronic inflammation is thought to play a major role in the progression of OA. By persistently suppressing inflammation, we believe that FX201 has the potential to both reduce pain and possibly modify disease progression. We acquired the rights to FX201 via a definitive agreement with GeneQuine Biotherapeutics GmbH, or GeneQuine, and have an exclusive license to the underlying intellectual property rights for human use of FX201 from Baylor College of Medicine in Houston, Texas. In ~~June,~~May 2019, the U.S. Patent and Trademark Office ~~(USPTO)~~ issued patent number 10,301,647, which covers the composition of matter and method of use of FX201 in the treatment of OA with a term through January 2033.

In March 2020, we initiated a Phase 1 single ascending dose (“SAD”) study to evaluate the safety and tolerability of FX201 in patients with painful OA of the knee. The multicenter, open-label study is ~~expected to evaluate~~evaluating three doses (low, mid and high dose) of FX201 in cohorts of five to eight patients. ~~The initial trial is expected to enroll approximately 15 to 24 patients with symptomatic knee OA who will be followed for 104 weeks. Clinical data from~~In addition, in the first ~~two cohorts indicate that FX201 appears to be generally safe and well-tolerated at the low and mid doses. There were no serious adverse events and there was no evidence~~quarter of ~~systemic biodistribution in plasma or shedding in urine observed in any patient. In February~~ 2021, ~~following an independent Data Monitoring Committee (DMC) review of the mid dose safety data,~~ we ~~announced the expansion of~~expanded the trial to include up to 20 additional patients in ~~each of~~both the low and mid dose treatment groups.

In ~~March~~June 2021, the ~~first patient~~SAD phase of the study was fully enrolled, and, as of November 1, 2021, 65 patients had been treated across all cohorts including the expansion groups. The most commonly observed treatment-related adverse events (“AEs”) observed in the ~~high dose cohort.~~

~~On May 11,~~trial have been pain, swelling, and effusion, and, in the second quarter, we made the strategic decision to investigate pretreatment with an intra-articularly administered immediate-release steroid prior to FX201 administration as a means to mitigate potential AEs. We expect to treat up to 38 patients with a pretreatment regimen. In October 2021, we presented ~~preliminary~~initial data from the mid-dose cohort of the open-label FX201 ~~data~~Phase 1 single ascending dose phase of the trial in patients with knee OA via a poster at the 2021 ~~American~~European Society of Gene & Cell Therapy ~~(ASGCT)~~(ESGCT) annual meeting. ~~Key findings from~~Preliminary results indicate that seven of eight patients treated with the ~~Phase 1 dose-escalation study evaluating the safety and tolerability~~mid dose of FX201 experienced a reduction of pain and functional improvement from baseline out to Week 24. The mid dose of FX201 was generally well-tolerated in all eight patients with moderate-to-severe knee ~~OA include:~~

In May 2021, one participant in the high-dose cohort experienced gastrointestinal bleeding and atrial fibrillation, which required hospitalization. An adverse event resulting in hospitalization is deemed serious; however, the investigator determined it to be unrelated to the study drug. As dictated by the protocol, any serious adverse event (SAE), regardless of relatedness, requires a pause in study enrollment, followed by a review of the event by the independent Data Monitoring Committee (DMC) for the study and FDA. Both the DMC and FDA agreed with the investigator’s assessment and endorsed the re-initiation of the trial, and enrollment has resumed.

Additional data readouts are expected by the end of 2021, including the interrogation of synovial fluid from patients to assess biological activity of FX201 locally in the joint and potential correlation with clinical endpoints over time.

FX301 (funapide in a proprietary thermosensitive hydrogel) – Locally Administered NaV1.7 Inhibitor for the Treatment of Post-Operative Pain

In September 2019, we entered into a definitive agreement with Xenon Pharmaceuticals that provides us with the global rights to develop and commercialize XEN402, a NaV1.7 inhibitor, for control of post-operative pain. Our investigational product candidate, known as FX301, consists of funapide formulated for extended release from a Flexion proprietary thermosensitive hydrogel for administration as a peripheral nerve block for control of post-operative pain. Within minutes following injection, the thermosensitive formulation has been shown to transition from a liquid to a gel, an effect that we believe can provide local delivery of funapide near target nerves for up to a week. Unlike typical local anesthetics, the selective pharmacology of funapide has the potential to provide effective pain relief while preserving motor function. As such, we believe FX301 could enable ambulation, rapid discharge, and early rehabilitation following musculoskeletal surgery.

In a validated post-operative pain model in pigs, a single injection of FX301 provided both greater analgesic effect from 12 through 72 hours and a longer duration of effect through 72 hours compared to liposomal bupivacaine or placebo. In addition, treatment with FX301 did not significantly affect total walking distance in animals at 2 and 24 hours post-injection, whereas animals treated with liposomal bupivacaine experienced a significant reduction in total walking distance compared with baseline at 2 and 24 hours post-injection.

These data formed the basis of our ~~Investigational New Drug (IND)~~IND application for FX301, which the FDA cleared in February 2021. In March 2021, we announced the treatment of the first patient in a Phase 1b proof-of-concept trial evaluating the safety and tolerability of FX301 administered as a single-dose, popliteal fossa block (a commonly used nerve block in foot and ankle-related surgeries) in patients undergoing bunionectomy. The Phase 1b randomized, double-blind, placebo-controlled study ~~will be~~is being conducted in two parts, ~~beginning with a single ascending dose~~the SAD portion ~~which will investigate~~investigated FX301 at low and high doses of funapide administered at two volumes in four cohorts of patients undergoing bunionectomy. A total of 48 patients (12 patients per cohort), ~~will be~~were randomized to receive either FX301 or placebo. A Safety Monitoring Committee ~~will review~~reviewed data from each dose cohort before the study ~~escalates~~escalated into higher doses. ~~The data from~~In July 2021, we fully enrolled the ~~single ascending dose~~SAD portion of the trial, and following an assessment of safety, systemic exposure and efficacy data by an internal review committee, we made the decision to expand the study. In the expansion cohort, an additional 36 patients will be ~~reviewed and a decision made regarding expanding a~~randomized (1:1) to receive either FX301 at the selected dose (130 mg/low volume) or placebo to further assess the safety, tolerability, systemic exposure, and ~~volume cohort by another 36 patients. This would support broader understanding~~efficacy of FX301 as a single-injection analgesic nerve block adjacent to the sciatic nerve of the ~~safety and efficacy~~popliteal fossa. Based on the current pace of enrollment in ~~that cohort. Results from this trial could potentially be~~the expansion cohort, we anticipate having data available in ~~late 2021.~~the first quarter of 2022.

Net product sales consist of sales of ZILRETTA, which was approved by the FDA on October 6, 2017, and launched in the United States in October 2017. We had not generated any revenue prior to the launch of ZILRETTA.

On March 30, 2020, we entered into an exclusive license agreement with HK Tainuo and Jiangsu Tainuo, a subsidiary of China Shijiazhuang Pharmaceutical Co, Ltd., for the development and commercialization of ZILRETTA in Greater China (consisting of mainland China, Hong Kong and Macau, and Taiwan). Under the terms of the agreement, HK Tainuo paid us an upfront payment of $10.0 million, of which $5.0 million was received as of June 30, 2020, and the remaining $5.0 million was received as of September 30, 2020. We are also eligible to receive up to $32.5 million in aggregate development, regulatory, and commercial sales milestone payments. All payments received from HK Tainuo are subject to ~~the~~ applicable Hong Kong withholding taxes. HK Tainuo is responsible for the clinical development, product registration, and commercialization of ZILRETTA in Greater China, and Jiangsu Tainuo serves as the guarantor of HK Tainuo’s obligations and responsibilities under the agreement. We are solely responsible for the

manufacture and supply of ZILRETTA to HK Tainuo for all clinical and commercial activities. The terms related to product manufacturing and supply, including pricing and minimum purchase requirements agreed to in the license agreement, will be covered by a separate supply agreement. All amounts owed to us are nonrefundable and non-creditable once paid. We concluded that the license and supply obligations were not distinct performance obligations, and therefore the transaction price will be recognized as revenue as our supply obligation is fulfilled over the term of the supply agreement, which has not yet commenced. No revenue was recognized associated with this contract as of ~~March 31,~~September 30, 2021.

Cost of sales consists of third-party manufacturing costs, freight, and indirect overhead costs associated with sales of ZILRETTA. Cost of sales also includes period costs related to certain inventory manufacturing services, inventory adjustment charges, and unabsorbed manufacturing and overhead costs, as well as any write-offs of inventory that fails to meet specifications or is otherwise no longer suitable for commercial manufacture.

Our research and development activities include: preclinical studies, clinical trials, and chemistry, manufacturing, and controls, or CMC, activities. Our research and development expenses consist primarily of:

We expense research and development expenses as incurred. Our direct research and development expenses consist primarily of external-based costs, such as fees paid to investigators, consultants, investigative sites, CROs, and companies that manufacture our clinical trial materials and potential future commercial supplies and are tracked on a program-by-program basis. We do not allocate personnel costs, facilities, or other indirect expenses to specific research and development programs. These indirect expenses are included within the amounts designated as “Personnel and other costs” in the Results of Operations section below. Inventory acquired prior to receipt of the marketing approval of a product candidate is recorded as research and development expense as incurred.

Our research and development expenses are expected to increase ~~relative to the prior year and~~ for the foreseeable future. Due to the expense reduction measures taken in 2020 in response to the COVID-19 pandemic, in particular a deferral of spending related to clinical trials, research and development expenses were lower than pre-pandemic levels. While the duration of COVID-19 and its impact on our ability to conduct clinical development are highly uncertain, we expect that a return to normal operations will likely result in an increase in future research and development expenses. Specifically, our costs will increase as we conduct additional clinical trials for ZILRETTA, including our planned registration trial in shoulder OA, and conduct further development activities for our pipeline programs, including our on-going clinical trials of ~~FX2021~~FX201 and FX301.

We cannot determine with certainty the duration of and completion costs associated with ongoing and future clinical trials or the associated regulatory approval process, post-marketing development of ZILRETTA, or development of any product candidates in our pipeline. The duration, costs, and timing associated with the further development of ZILRETTA or the development of other product candidates will depend on a variety of factors, including uncertainties associated with the results of our clinical ~~trials.~~trials, as well as the status and timing of the Merger. As a result of these uncertainties, we are currently unable to estimate with any precision our future research and development expenses for expanded indications for ZILRETTA or the product candidates in our pipeline.

Selling, general and administrative expenses consist primarily of personnel costs, including salaries, sales commissions, related benefits, travel expenses, and stock-based compensation of our executive, finance, business development, commercial, information technology, legal, and human resources functions. Other selling, general and administrative expenses include an allocation of facility-related costs, patent filing expenses, and professional fees for legal, consulting, auditing, and tax services.

We anticipate that ~~our~~ selling, general, and administrative expenses will increase inas compared to the foreseeable future as we continue to build our corporate and commercial infrastructure to support the continued development and commercialization of ZILRETTA and other product candidates. In 2020, as a result of the adverse effect of COVID-19 on our revenues, we took steps to reduce our sales and marketing expenses through the elimination of live presence at medical and industry conferences, reductions in in-person physician speaker programs and reductions in select marketing programs and materials. While certain selling and marketing activities have resumed, travel is still restricted in many areas and all conferences and speaker programs remain virtual, resulting in operating expenses for the first quarter of 2021 that were lower than pre-pandemic levels. We cannot determine with certainty the duration and timing of COVID-19, but we expect that a return to normal operations will likely result in an increase in future selling, general, and administrative expenses,prior year, including external marketing expenses and the operation of our field sales force.

Interest income consists of interest earned on our cash and cash equivalents balances and our marketable securities. The primary objective of our investment policy is capital preservation.

Interest expense consists of contractual interest on our 2024 Convertible Notes, which accrue interest at a rate of 3.375% per annum, payable semi-annually, our term loan facility, which, accrues interest at a floating interest rate equal to the greater of the ~~Prime Rate (as~~prime rate as reported in the Wall Street ~~Journal)~~Journal plus ~~1.50%~~2.75% or ~~6.50%~~6.0% per annum, and our revolving credit facility, which accrues interest at a

floating interest rate equal to the greater of the ~~Prime Rate (as~~prime rate as reported in the Wall Street ~~Journal)~~Journal plus 1.75% or ~~5.50%~~5.0% per annum. Also included in interest expense is the amortization of the final payment on the 2021 term loan, the loss on debt extinguishment related to the 2019 term loan, and the debt discount related to the convertible notes, which is being amortized to interest expense using the effective interest method over the expected life of the debt.

We maintain a bank account denominated in British Pounds. All foreign currency payables and cash balances are measured at the applicable exchange rate at the end of the reporting period. All associated gains and losses from foreign currency transactions are reflected in the consolidated statements of operations, within other income and expense.

Other income (expense) consists of the amortization of premiums or accretion of discounts related to our marketable securities, ~~and our~~ realized gains (losses) on redemptions of our marketable ~~securities. We will continue to record either income or expense related to accretion of discounts or amortization of premiums on marketable~~ securities, ~~for as long as we hold these investments. Also included in other income (expense) is~~gains (losses) from foreign currency transactions, and the amortization of debt issuance costs on ~~our term loan facility and~~ the 2024 Convertible Notes, which are being amortized over the ~~respective terms~~term of the ~~loans.~~loan.

The provision for income taxes consists of foreign withholding taxes related to our license agreement with HK Tainuo.

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements and the reported revenue and expenses during the reported periods. We evaluate these estimates and judgments, including those described below, on an ongoing basis. We base our estimates on historical experience, known trends and events, contractual milestones, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that the estimates, assumptions, and judgments involved in the accounting policies described in Management’s Discussion and Analysis of Financial Condition and Results of Operations in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2020, have the greatest potential impact on our financial statements, so we consider them to be our critical accounting policies and estimates. There were no material changes to our critical accounting policies and estimates during the ~~three~~nine months ended ~~March 31,~~September 30, 2021.

Comparison of the Three and Nine Months Ended ~~March 31,~~September 30, 2021 and 2020

The following tables summarize our results of operations for the three and nine months ended ~~March 31,~~September 30, 2021:


	Three Months Ended March 31,												Three Months Ended September 30,
(In thousands)	2021			2020			Change			% Increase/ (Decrease)			2021			2020			Change			% Increase/ (Decrease)
Revenues:
Product revenue, net	$	24,589		$	20,127		$	4,462			22.2	%	$	21,326		$	23,664		$	(2,338	)		(9.9	)%
Operating expenses:
Cost of sales		6,085			2,276			3,809			167.4	%		3,727			5,130			(1,403	)		(27.3	)%
Research and development		14,047			21,134			(7,087	)		(33.5	)%		14,771			10,092			4,679			46.4	%
Selling, general and administrative		27,598			29,299			(1,701	)		(5.8	)%		26,986			27,312			(326	)		(1.2	)%
Total operating expenses		47,730			52,709			(4,979	)		(9.4	)%		45,484			42,534			2,950			6.9	%
Loss from operations		(23,141	)		(32,582	)		9,441			(29.0	)%		(24,158	)		(18,870	)		(5,288	)		28.0	%
Other (expense) income:
Interest income		300			427			(127	)		(29.7	)%		54			62			(8	)		(12.9	)%
Interest expense		(5,189	)		(4,721	)		(468	)		9.9	%		(5,787	)		(5,125	)		(662	)		12.9	%
Other expense (income)		(526	)		74			(600	)	NM
Other expense														(421	)		(457	)		36			(7.9	)%
Total other (expense) income		(5,415	)		(4,220	)		(1,195	)		28.3	%		(6,154	)		(5,520	)		(634	)		11.5	%
Loss before income taxes														(30,312	)		(24,390	)		(5,922	)		24.3	%
Income tax expense														—			248			(248	)	NM
Net loss	$	(28,556	)	$	(36,802	)		8,246			(22.4	)%	$	(30,312	)	$	(24,638	)		(5,674	)		23.0	%

The following table presents the adjustments deducted from gross product revenue to arrive at net product revenue for sales of ZILRETTA during the three and nine months ended ~~March 31,~~September 30, 2021 and 2020:

Net product revenue for the three months ended ~~March 31,~~September 30, 2021 and 2020, was ~~$24.6~~$21.3 million and ~~$20.1~~$23.7 million, respectively. The number of ZILRETTA units sold period-over-period increased, which resulted in an increase in net revenue of $1.6 million, offset by

a decrease of $3.9 million, which was attributable to a decrease in the net price per unit. The decrease in net price was due to an increase in returns of short-dated product, which resulted in a reduction of revenue of $3.4 million for the three months ended September 30, 2021. The decrease in net price was also attributed to the increase in rebates and discounts offered to healthcare providers, partially offset by an increase in our gross sales price in the third quarter of 2021.

Net product revenue for the nine months ended September 30, 2021 and 2020, was $74.1 million and $59.2 million, respectively. The period-over-period increase was due to an increase in the number of ZILRETTA units sold, which resulted in an increase in net revenue of ~~$5.9~~$20.3 million, offset by a decrease of ~~$1.4~~$5.5 million, which was attributable to a decrease in the net price per unit primarily due to provider rebate offerings and other ~~discounts. We are unable~~discounts and the aforementioned charge relating to ~~predict~~product returns, partially offset by an increase in our gross sales price in the ~~long-term~~third quarter of 2021. Net revenue for the nine months ended September 30, 2020, included the adverse impact of COVID-19 ~~and~~on the ~~pace~~operations of ~~recovery and how this may impact purchases of ZILRETTA by~~ healthcare providers, which resulted in a material decline in net revenue as ~~individual providers and their patients have had different responses~~compared to ~~the pandemic.~~ our prior expectations.

For further discussion regarding our revenue recognition policy, see Note 2, “Summary of Significant Accounting Policies,” in the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q.

Cost of sales was ~~$6.1~~$3.7 million and ~~$2.3~~$5.1 million for the three months ended ~~March 31,~~September 30, 2021 and 2020, respectively. For the three months ended ~~March 31,~~September 30, 2021, cost of sales was comprised of ~~$2.5~~$1.8 million related to the actual cost of units sold and $0.7 million of period costs and other adjustments. In addition, cost of sales for the three months ended September 30, 2021 included a charge of $1.2 million related to the write-down of short-dated inventory that will not be sold prior to expiry. For the three months ended September 30, 2020, cost of sales was comprised of $2.0 million related to the actual cost of units sold and $3.1 million of unabsorbed overhead associated with the voluntary, temporary suspension of manufacturing activities at Patheon due to COVID-19 impacts on sales of ZILRETTA.

Cost of sales was $14.8 and $12.9 million for the nine months ended September 30, 2021 and 2020, respectively. For the nine months ended September 30, 2021, costs of sales consisted of $7.1 million related to the actual cost of units sold, $5.2 million of unabsorbed manufacturing and overhead costs related to the operation of the facility at Patheon, ~~and a charge resulting from~~$1.8 million related to the write-down of short-dated inventory that iswill not ~~expected to~~ be sold prior to expiry, and $0.7 million of ~~$0.5 million.~~period costs and other adjustments For the ~~three~~nine months ended ~~March 31,~~September 30, 2020, cost of sales ~~was $2.3 million which was comprised~~consisted of ~~$2.0~~$5.6 million related to the actual cost of units sold, $6.5 million of unabsorbed manufacturing overhead, and ~~$0.3~~$0.8 million of period costs and ~~other~~ adjustments.


	Three Months Ended March 31,										Three Months Ended September 30,
(In thousands)	2021		2020		Change			% Increase/ (Decrease)			2021		2020		Change		% Increase/ (Decrease)
Direct research and development expenses by program:
ZILRETTA	$	1,185	$	4,826	$	(3,641	)		(75.4	)%	$	1,675	$	1,043	$	632		60.6	%
FX201		1,468		3,716		(2,248	)		(60.5	)%		3,358		831		2,527		304.1	%
FX301		4,143		1,722		2,421			140.6	%		1,839		1,160		679		58.5	%
Portfolio expansion		176		176	—			—				226		72		154		213.9	%
Other		459		640		(181	)		(28.3	)%		630		386		244		63.2	%
Total direct research and development expenses		7,431		11,080		(3,649	)		(32.9	)%		7,728		3,492		4,236		121.3	%
Personnel and other costs		6,616		10,054		(3,438	)		(34.2	)%		7,043		6,600		443		6.7	%
Total research and development expenses	$	14,047	$	21,134	$	(7,087	)		(33.5	)%	$	14,771	$	10,092	$	4,679		46.4	%

Research and development expenses were ~~$14.0~~$14.8 million and ~~$21.1~~$10.1 million for the three months ended ~~March~~ September 30, 2021 and 2020, respectively. For the three months ended September 30, 2021, development expenses for ZILRETTA increased by $0.6 million due to an increase in ZILRETTA life cycle management activities. Program expenses related to FX201 and FX301 increased by $2.5 million

and $0.7 million, respectively, due to an increase in clinical trial activity, and portfolio expansion-related expenses increased by $0.4 million. Personnel and other costs also increased by $0.4 million due to an increase in salary and other employee-related costs and stock-based compensation expense.

Research and development expenses were $41.5 million and $43.7 million for the nine months ended September 30, 2021 and 2020, respectively. The decrease in research and development ~~expenses~~expense of ~~$7.1~~$2.2 million was primarily due to a decrease of ~~$3.6~~$3.9 million in development ~~expenses~~expense for ZILRETTA due to a reduction in ZILRETTA life cycle management activities, and a decrease of $2.2 million related to FX201 program costs, which is largely due to the $2.5 million milestone payment related to dosing the first human patient in the Phase 1 clinical trial which occurred in the first quarter of 2020, as well as a decrease of $3.4$3.5 million in salary and other employee-related costs and stock-based compensation expense related to lower headcount. Decreases were partially offset by an increase of ~~$2.4~~$0.9 million related to FX201 due to increased clinical trial activity in ~~expenses~~2021, offset by the $2.5 million milestone payment related to dosing the first human patient in the Phase 1 clinical trial that occurred in the first quarter of 2020 and an increase of $3.5 million related to FX301, which is attributed to the achievement of certain development milestones, including the clearing of the IND by FDA and the initiation of the Phase 1b clinical trial, both of which occurred in the first quarter of ~~2021.~~2021, and a $0.7 million increase in costs related to our portfolio expansion.

Selling, general and administrative expenses were ~~$27.6~~$27.0 million and ~~$29.3~~$27.3 million for the three months ended ~~March 31,~~September 30, 2021 and 2020, respectively. Selling expenses were ~~$19.1~~$17.8 million and ~~$20.5~~$19.3 million for the three months ended ~~March 31,~~September 30, 2021 and 2020, respectively. The ~~year over year~~year-over-year decrease in selling expenses of ~~$1.4~~$1.5 million was primarily due to lower headcount, partially offset by the ~~fact that the majority~~resumption of industry conferences and physician speaker programs ~~remained virtual due to COVID-19,~~ and ~~although more physician offices are opening,~~

increase in business ~~travel remains low compared to pre-pandemic levels.~~travel. General and administrative expenses were ~~$8.5~~$9.2 million and ~~$8.8~~$8.0 million for the three months ended ~~March 31,~~September 30, 2021 and 2020, respectively, which represents ~~a decrease~~an increase of ~~$0.3~~$1.2 million. The increase was largely attributable to acquisition costs related to the merger agreement with Pacira.

Selling, general and administrative expenses were $82.0 million and $81.3 million for the nine months ended September 30, 2021 and 2020, respectively. Selling expenses were $55.7 million and $56.5 million for the nine months ended September 30, 2021 and 2020, respectively. The year-over-year decrease in selling expenses of $0.8 million was primarily due to lower headcount and a reduction in operating expenses, partially offset by the partial resumption of industry conferences and physician speaker programs and increases in business travel. General and administrative expenses were $26.3 million and $24.8 million for the nine months ended September 30, 2021 and 2020, respectively, which represents an increase of $1.5 million. The year-over-year increase was largely attributable to acquisition costs related to the merger agreement with Pacira.

Interest income was ~~$0.3~~$0.1 million ~~and $0.4 million~~ for each of the three months ended ~~March 31,~~September 30, 2021 and 2020, respectively. ~~The~~Interest income was $0.5 million and $0.6 million for the nine months ended September 30, 2021 and 2020.The decrease in interest income was primarily due to a decrease in the average investment balance as well as a decrease in interest rates over the ~~period.~~period

Interest expense was ~~$5.2~~$5.8 million and ~~$4.7~~$5.1 million for the three months ended ~~March 31,~~September 30, 2021 and 2020, respectively. Interest expense was $16.2 million and $14.8 million for the nine months ended September 30, 2021 and 2020, respectively. The increase in interest expense ~~can be~~was attributed to the ~~restructuring~~loss on debt extinguishment of ~~our 2019 term loan~~$0.5 million recorded in ~~May 2020,~~connection with the 2021 Amended Credit Agreement, which resulted in ~~interest being paid~~the partial repayment of the final payment owed on ~~a higher principal amount.~~the prior term loan agreement, as well as an increase in the amortization of the debt discount on the 2024 Convertible Notes.

We recorded other expense of $0.4 million for the three months ended September 30, 2021, compared to $0.5 million for the three months ended ~~March 31, 2021, compared to other income of $0.1~~September 30, 2020. Other expense was $1.3 million and $0.6 million for the ~~three~~nine months ended ~~March 31, 2020.~~September 30, 2021 and 2020, respectively. The increase in other expense was primarily due to changes in the price of debt securities, resulting in increased amortization of premiums, ~~rather than accretion of discounts,~~ as well as an increase in ~~losses on~~ foreign currency ~~transactions~~losses due to ~~an increase in~~ exchange ~~rates.~~rate fluctuations.

For the ~~three~~nine months ended ~~March 31,~~September 30, 2021, we generated ~~$24.6~~$74.1 million in net product revenue. We have incurred significant net losses in each year since our inception, including net losses of $113.7 million, $149.8 million, and $169.7 million, for fiscal years 2020, 2019, and 2018, respectively, and ~~$28.6~~$81.1 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2021. As of ~~March 31,~~September 30, 2021, we had an accumulated deficit of ~~$810.9~~$863.4 million. We anticipate that we will continue to incur losses over the next few years.

Since our inception through ~~March 31,~~September 30, 2021, we have funded our operations primarily through the sale of our common stock and convertible preferred stock and convertible debt, and through venture debt financing, including amounts from our initial and follow-on public offerings, ~~during 2014, 2016, 2017, and most recently in May 2020,~~ as well as our term loan ~~facility entered into in 2015~~ and ~~2019~~revolving credit facility and our 2024 Convertible Notes ~~issuance in 2017.~~issuance. This funding is necessary to support the commercialization of ZILRETTA and to perform the research and development activities required to develop our other product candidates in order to generate potential future revenue streams. We may not be able to obtain financing on acceptable terms, or at all. In particular, as a result of the ~~COVID-19~~COVID‑19 pandemic and actions taken to slow its spread, the global credit and financial markets have experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any additional debt or equity financing more difficult, more costly, and more dilutive.

We expect that our research and development ~~and selling, general and administrative~~ expenses will increase in 2021 and beyond and, as a result, we may need additional capital to fund our operations, which we may seek to obtain through one or more equity offerings, debt and convertible debt financings, government or other third-party funding, and licensing or collaboration arrangements.

~~As of March 31, 2021, we had cash, cash equivalents, and marketable securities of $154.3 million. Based on~~If the recent decrease in revenue as compared to our ~~current operating plan~~expectations continues, we anticipate that absent raising additional capital through financing or other transactions, our ~~existing~~ cash ~~cash equivalents, and marketable securities will fund our operations for at least~~balance is likely to decrease below $100.0 million within the next ~~12 months from the issuance date of the financial statements included in~~twelve months. If this ~~report. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with an objective of capital preservation.~~

On August 2, 2019, we entered into the Amended and Restated Credit and Security Agreement with Silicon Valley Bank, MidCap Financial Trust, Flexpoint MCLS Holdings, LLC, and the other Lenders, providing for a term loan of $40.0 million and a revolving credit facility of up to $20.0 million, both of which mature on January 1, 2024. We concurrently borrowed the $40.0 million term loan and used $7.7 million of the proceeds to repay the remaining amount owed on our existing term loan with Silicon Valley Bank and MidCap Funding XIII Trust. The revolving credit facility became available to us beginning January 1, 2020, and in February 2020, we borrowed the full $20.0 million available under the revolver.

On May 18, 2020, we entered into an amendment to the amended and restated credit and security agreement (the “amendment”). Pursuant to the amendment, we borrowed $15.0 million under a new term loan advance and immediately used the proceeds to repay an equal amount under the revolving credit facility, and the maximum principal amount of the revolving credit facility was reduced from $20.0 million to $5.0 million. The new term loan is subject to substantially the same terms, including interest rate, amortization and maturity date, as the existing term loan under the credit facility. Additionally, if our liquidity (as defined in Note 9 to our unaudited consolidated financial statements included elsewhere in this report) should decrease below $80.0 million,occurs, under the terms of the ~~amended and restated credit and security agreement,~~2021 Amended Credit Agreement, we would become subject to a minimum revenue ~~covenant.~~covenant and we believe there is substantial risk that we would fail to meet the minimum revenue covenant at that time or shortly thereafter. If we become subject to the minimum revenue covenant and fail to comply with it, the lenders could elect to declare all amounts outstanding to be immediately due and payable. While we would expect to request a waiver from the lenders, there can be no assurances that such a request would be granted or would not be conditioned on additional terms or concessions, or that we would be able to raise additional capital to avoid application of the minimum revenue covenant. These conditions raise substantial doubt about our ability to continue as a going concern for a period of one year after the date that the financial statements are issued.

As of September 30, 2021, we had cash, cash equivalents, and marketable securities of $142.1 million. Management believes that current cash, cash equivalents, and marketable securities on hand at September 30, 2021, and taking into account our plans to reduce operating expenses, request a waiver of the minimum revenue covenant from the lenders, and remain opportunistic with respect to raising additional capital through financing or other transactions, should be sufficient to fund operations for at least the next twelve months from the issuance date of these financial statements. However, as we are expecting to close the planned merger with Pacira prior to the end of 2021, none of the above actions have been taken or have been approved to be taken and therefore cannot be considered in Management’s going concern evaluation as a mitigating action.

We have concluded that without taking into consideration the planned merger with Pacira, Management’s plans do not alleviate the substantial doubt about our ability to continue as a going concern. As the planned merger transaction with Pacira has not occurred as of the issuance of these financial statements, it also cannot be considered within Management’s plans to alleviate the conditions raised around substantial doubt. As a result, in accordance with the requirements of ASC 205-40, management has concluded that it is required to disclose that substantial doubt exists about our ability to continue as a going concern for one year from the date the financial statements included in this report are issued.

Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with an objective of capital preservation.

On July 30, 2021, we entered into a second amendment (the “2021 Amended Credit Agreement”) to our Amended and Restated Credit and Security Agreement (the “Existing Credit Agreement”) with Silicon Valley Bank, as agent and lender, MidCap Financial Trust, MidCap Funding XIII Trust, and the other lenders from time to time party thereto (collectively, the “Lenders”), providing for a term loan facility of up to $75.0 million, with $55.0 million available at closing and an additional $20.0 million (the “second tranche”) available upon positive Phase 1 clinical trial data in either of our two pipeline programs, FX201 and FX301, sufficient to initiate a Phase 2 clinical study, and a revolving credit facility of up to $25.0 million, both of which mature on February 1, 2024, which may be extended to July 1, 2026, upon satisfaction of certain specified conditions set forth in the 2021 Amended Credit Agreement (the “Maturity Date”). We concurrently borrowed the $55.0 million term loan (the “2021 term loan”), simultaneously used $48.1 million of the proceeds to repay the outstanding term loan under the Existing Credit Agreement, and drew down $20.0 million from the revolving credit facility, bringing the total revolver balance to $25.0 million.

The 2021 Amended Credit Agreement contains certain representations, warranties, and covenants, including a minimum revenue covenant that will be in effect at any time our liquidity (defined as cash, cash equivalents and marketable securities held with Silicon Valley Bank and certain accounts receivable as deemed eligible under the 2021 Amended Credit Agreement) is below $100.0 million (if the second tranche is undrawn) or $120.0 million (if the second tranche is drawn). Additionally, if our liquidity is below ~~$80.0~~$100.0 million, all amounts received from customer collections will be applied immediately to reduce the revolving credit ~~facility~~facility. The minimum revenue covenant, if it applies in the future, is applied to the trailing six-months of net revenue and is determined based on our approved forecast, as determined by the Lenders. If the revenue covenant becomes applicable and we fail to comply with it, the amounts due under the 2021 Amended Credit Agreement could be declared immediately due and payable..

Term loan borrowings under the ~~credit facility~~2021 Amended Credit Agreement accrue interest monthly at a floating interest rate equal to the greater of (i) the Prime Rate ~~(as reported in the Wall Street Journal)~~ plus ~~1.50%~~2.75% or ~~6.50%~~(ii) 6.00% per annum. Under the term loan credit facility, following an ~~18-month~~ interest-only period ending on August 1, 2023 (if the second tranche is undrawn) or August 1, 2024 (if the second tranche is drawn), principal is due in 36 equal monthly installments ~~commencing February 1, 2021, and ending on~~through the Maturity

Date. We may prepay the term loan at any time by paying the outstanding principal balance, a final payment equal to ~~6.75%~~4.75% of the term loan amount, all accrued interest, and a prepayment fee of 3% of the outstanding term loan amount if repaid in the first year, 2% of the outstanding term loan amount if repaid in the second year, and 1% of the outstanding term loan amount if repaid in the third year of the loan; no prepayment fee is required thereafter.

~~Borrowings~~Revolving borrowings under the ~~revolving credit facility~~2021 Amended Credit Agreement accrue interest monthly at a floating interest rate equal to the greater of (i) the Prime Rate ~~(as reported in the Wall Street Journal)~~plus 1.75% or ~~5.50%~~(ii) 5.00% per annum. The revolving credit facility is co-terminus with the term ~~loan.~~loan credit facility. If the interest payment on the revolving credit facility is less than the amount of interest that would have been payable had we borrowed 25% of the total ~~commitment~~commitments under the revolving credit facility, or the Revolving Commitment Amount, then we will be required to pay the difference. We are also required to pay a facility fee in respect of the revolving credit facility equal to 1%0.5% of the

Revolving Commitment Amount payable at closing and 0.5% of the Revolving Commitment ~~Amount.~~Amount payable on the first anniversary of closing. We may retire the revolving credit facility early, at any time, by paying the outstanding principal balance, all accrued interest, and a termination fee equal to 2% of the Revolving Commitment Amount if repaid in the first year, and 1% of the Revolving Commitment Amount if repaid in the second year; with no termination fee thereafter. To the extent any portion of the Revolving Commitment Amount is undrawn, we will be required to pay an “unused line fee” equal to 0.25% per annum of the average unused portion of the Revolving Commitment Amount, calculated on a calendar year basis as an amount equal to the difference between (i) the Revolving Commitment Amount and (ii) the greater of (A) 25.0% of the Revolving Commitment Amount, and (B) the average for the period of the daily closing balance of the Revolving Commitment Amount outstanding.

On November 4, 2020, we entered into ~~the~~a Distribution Agreement with Goldman Sachs & Co. LLC and Credit Suisse Securities (USA) LLC (collectively, the “Managers”) relating to the issuance and sale from time to time of up to $100,000,000 of shares of our common stock. Under the terms of the Distribution Agreement, we will pay the Managers a commission of up to 3% of the gross sales price of any shares sold. As of ~~March 31,~~September 30, 2021, 134,048 shares had been sold under the Distribution Agreement, for total net proceeds of $1.7 million.

We are subject to a variety of specified liquidity and capitalization restrictions under the Merger Agreement. Unless we obtain Pacira’s prior written consent (which consent may not be unreasonably withheld, conditioned or delayed) and except (i) as required or expressly contemplated by the Merger Agreement, (ii) as required by applicable law or (iii) as set forth in the confidential disclosure schedule we delivered to Pacira, we may not, among other things and subject to certain exceptions and aggregate limitations, incur additional indebtedness, issue additional shares of our common stock outside of our equity incentive plans, repurchase our common stock, pay dividends, acquire assets, securities or property, dispose of businesses or assets, enter into material contracts or make certain additional capital expenditures.

The following table shows a summary of our cash flows for ~~each of~~ the ~~three~~nine months ended ~~March 31,~~September 30, 2021 and 2020:

Operating activities used ~~$18.5~~$51.4 million of cash in the ~~three~~nine months ended ~~March 31,~~September 30, 2021. Cash used in operating activities resulted primarily from our net loss for the period of ~~$28.6~~$81.1 million, partially offset by changes in our operating assets and liabilities of ~~$1.0~~$2.9 million and non-cash charges of ~~$9.1~~$26.7 million. Changes in our operating assets and liabilities consisted primarily of a ~~$2.2~~$0.7 million decrease in ~~inventory~~accounts receivable and an increase of ~~$1.7~~$6.0 million in accounts payable and accrued ~~expenses,~~expense, partially offset by a ~~$0.3 million increase in accounts receivable, a $2.2~~$1.5 million increase in prepaid expenses and other current assets, a $1.0 million increase in inventory, and a ~~$0.4~~$1.1 million decrease in lease liabilities primarily due to principal lease payments. Our non-cash charges consisted primarily of ~~$4.6~~$12.8 million of stock-based compensation expense, ~~$2.5~~$7.8 million related to the amortization of the debt discount and debt issuance costs related to the 2024 Convertible Notes, ~~$0.4~~$1.3 million related to the amortization of right-of-use assets, ~~$0.5~~$1.6 million of depreciation, ~~$0.2~~$0.5 million of non-cash interest expense related to amortization of the final payment due on the ~~2019~~2021 term loan, ~~and $0.2~~$0.4 million of amortization of premiums paid for the purchase of marketable ~~securities.~~securities, $0.5 million related to the loss of debt extinguishment, and $1.8 million related to the provision for inventory for the write-down of short-dated ZILRETTA inventory that is not expected to be sold prior to expiry.

Operating activities used ~~$28.2~~$60.8 million of cash in the ~~three~~nine months ended ~~March 31,~~September 30, 2020. ~~Cash~~The cash flow used in operating activities resulted primarily from our net loss for the period of ~~$36.8~~$94.1 million, ~~and~~partially offset by changes in our operating assets and liabilities of ~~$0.8~~$10.1 million ~~offset by~~and non-cash charges of ~~$7.8~~$23.1 million. Changes in our operating assets and liabilities consisted primarily of a ~~$6.8~~$9.2 million decrease in accounts receivable, and a $10.0 million increase in ~~accounts receivable,~~deferred revenue related to the license agreement with HK Tainuo, partially offset by a ~~$3.1~~$1.1 million increase in inventory, a ~~$0.4~~$0.5 million increase in prepaid expenses and other current assets, a decrease of ~~$2.0~~$6.5 million in accounts payable and accrued expenses and a ~~$0.4~~$1.0 million decrease in lease liabilities and other long-term liabilities primarily due to principal lease payments. Our non-cash charges consisted primarily of ~~$4.7~~$13.4 million of stock-based compensation expense, ~~$2.3~~$6.9 million related to the amortization of the debt discount and debt issuance costs related to the 2024 Convertible Notes, ~~$0.4~~$1.2 million related to the amortization of right-of-use assets, ~~$0.2~~$1.3 million of depreciation, ~~$0.1~~$0.5 million of non-cash interest expense related to amortization of the final payment due on the 2019 term loan and $0.3 million related to the loss on disposal of fixed assets, partially offset by ~~$0.1~~$0.5 million of ~~net accretion~~premiums paid for the purchase of ~~discounts related to our investments.~~marketable securities.

Net cash provided by investing activities was ~~$10.9~~$60.2 million in the ~~three~~nine months ended ~~March 31,~~September 30, 2021. Net cash provided by investing activities consisted primarily of cash received for the redemption and sale of marketable securities of ~~$13.8~~$67.1 million, partially offset by cash used to purchase marketable securities of ~~$2.0~~$5.2 million and capital expenditures of ~~$0.8~~$1.7 million, primarily relating to the purchase of equipment associated with the expansion of our manufacturing facilities at Patheon.

Net cash ~~provided by~~used in investing activities was ~~$38.0~~$10.7 million in the ~~three~~nine months ended ~~March 31,~~September 30, 2020. Net cash ~~provided by~~used in investing activities consisted primarily of ~~cash received for the redemption and sale~~purchases of marketable securities of ~~$41.2~~$56.2 million ~~partially offset by $3.2 million of cash used for~~and capital expenditures of $8.9 million, primarily relating to the purchase of equipment associated with the expansion of our manufacturing facilities at Patheon. These expenses were partially offset by cash received for the redemption and sale of marketable securities of $54.4 million.

Net cash ~~used in~~provided by financing activities was ~~$1.5~~$20.3 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2021, which consisted of ~~$3.1~~$55.0 million ~~related the payment~~and $20.0 million of ~~principal on our 2019~~additional term loan and ~~public offering costs paid during~~revolving credit facility borrowings, respectively, under the ~~period of $0.1~~2021 Amended Credit Agreement, $0.9 million ~~partially offset by~~related to employee stock purchases through our employee stock purchase plan, and $1.7 million related to the net proceeds received from the sale of common stock under our Distribution Agreement. Increases were partially offset by a decrease of $56.9 million of principal payments and partial repayment of the final payment under the 2019 term loan, $0.2 million related the payment of debt issuance costs related to the 2021 Amended Credit Agreement, and $0.1 million of public offering costs paid during the period.

Net cash provided by financing activities was ~~$20.0~~$117.9 million for the ~~three~~nine months ended ~~March 31,~~September 30, 2020, of which $97.2 million related to the ~~total amount~~net proceeds received from the offering of our common stock, partially offset by public offering costs paid during the period of $0.4 million, $0.1 million received from the exercise of stock options and $0.9 million relating to employee stock purchases through our employee stock purchase plan, as well as $20.0 million borrowed under the revolving credit facility associated with our 2019 term loan.

For a discussion of our contractual obligations, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2020 Annual Report on Form 10-K. There have not been any material changes to such contractual obligations or potential milestone payments since December 31, 2020, other than as described in Notes 9, 12, and 13 to our unaudited consolidated financial statements included elsewhere in this report.

During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements.

Our primary exposures to market risk are interest income sensitivity and equity price risk. Interest income is affected by changes in the general level of U.S. interest rates. Due to the short-term duration of a majority of our investment portfolio and the low risk profile of our investments, an immediate 10.0% change in interest rates would not have a material effect on the fair market value of our portfolio. Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by a sudden change in market interest rates on our investment portfolio.

We do not believe that our cash, cash equivalents, and marketable securities have significant risk of default or illiquidity. While our cash and investments are invested with the goal of capital preservation, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits.

We have borrowed $55.0 million in term loans under our ~~credit facility.~~2021 Amended Credit Agreement. Term loan borrowings under the ~~credit facility~~2021 Amended Credit Agreement accrue interest monthly at a floating interest rate equal to the greater of (i) the ~~prime rate~~Prime Rate plus ~~1.5%~~2.75% or ~~6.5%~~(ii) 6.0% per annum.

We have borrowed ~~$5.0~~$25.0 million under the revolving credit facility. ~~Borrowings~~Under the 2021 Amended Credit Agreement, borrowings under the revolving credit facility accrue interest monthly at a floating interest rate equal to the greater of (i) the ~~prime rate~~Prime Rate plus 1.75% or ~~5.50%~~(ii) or 5.0% per annum. In addition to paying interest on any amounts borrowed under the revolving credit facility, we may in the future owe an unused revolving line facility fee equal to 0.25% per annum of the average unused portion of the revolving line, multiplied by the difference between the total amount available to be borrowed (the “Revolving Commitment Amount”) and the greater of the average outstanding revolver balance and 25% of the Revolving Commitment Amount.

On May 2, 2017, we issued $201.3 million aggregate principal amount of 2024 Convertible Notes. The 2024 Convertible Notes are senior unsecured obligations and bear interest at a rate of 3.375% per year, payable semi-annually in arrears on May and

November 1st of each year. The 2024 Convertible Notes will mature on May 1, 2024, unless repurchased or converted earlier. The 2024 Convertible Notes will be convertible into cash, shares of our common stock, or a combination thereof, at our election (subject to certain limitations in the 2015 term loan), at a conversion rate of approximately 37.3413 shares of common stock per $1,000 principal amount of the 2024 Convertible Notes, which corresponds to a conversion price of approximately $26.78 per share of our common stock and represents a conversion premium of approximately 35% based on the last reported sale price of our common stock of $19.72 on May 2, 2017, the date the 2024 Convertible Notes offering was priced. As of May 2, 2017, the fair value of the 2024 Convertible Notes was $136.7 million. Our 2024 Convertible Notes include conversion and settlement provisions that are based on the price of our common stock at conversion or at maturity of the 2024 Convertible Notes. The amount of cash we may be required to pay is

determined by the price of our common stock. The fair value of our 2024 Convertible Notes are dependent on the price and volatility of our common stock and will generally increase or decrease as the market price of our common stock changes. The estimated fair value of the 2024 Convertible Notes, face value of $201.3 million, was ~~$181.5~~$179.8 million at ~~March 31,~~September 30, 2021.

Most of our transactions are conducted in the U.S. dollar. We do have certain agreements with vendors located outside the United States, which have transactions conducted primarily in British Pounds and Euros. As of ~~March 31,~~September 30, 2021, we had ~~$1.2~~$2.5 million in liabilities denominated in British Pounds. A hypothetical 10% change in foreign exchange rates would result in a ~~$0.1~~$0.2 million change in the value of our liabilities. No other payables to vendors were denominated in currencies other than in U.S. dollars. As of ~~March 31,~~September 30, 2021, we had ~~$3.0~~$2.6 million of cash denominated in British Pounds. A hypothetical 10% change in foreign exchange rates would result in a $0.3 million change in the amount of cash denominated in British Pounds.

We are responsible for maintaining disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Disclosure controls and procedures are controls and other procedures designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on our management’s evaluation (with the participation of our principal executive officer and principal financial officer) of our disclosure controls and procedures as required by Rule 13a-15 under the Exchange Act, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective to achieve their stated purpose as of ~~March 31,~~September 30, 2021, the end of the period covered by this report.

There were no changes in our internal control over financial reporting during the quarter ended ~~March 31,~~September 30, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

WeBetween October 22, 2021, and November 10, 2021, eleven Complaints were filed in federal court by purported stockholders of the Company regarding the Merger. The Complaints name the Flexion Defendants (defined above as the Company and each member of our board of directors) as defendants. The Waterman complaint additionally names as defendants the Pacira Defendants. The plaintiffs generally contend that the Solicitation/Recommendation Statement on Schedule 14D-9 that we filed on October 22, 2021, omitted or misrepresented material information regarding the Merger. The Hart complaint additionally alleges that we engaged in an insufficient sales process and that members of our board of directors and our management had conflicts of interest with stockholders of the Company. The Complaints allege violations of Section 14(d) and/or Section 14(e) of the Exchange Act against all Flexion Defendants, and assert violations of Section 20(a) of the Exchange Act against the members of our board of directors. The Waterman complaint additionally alleges violations of Section 14(d), Section 14(e), and Section 20(a) of the Exchange Act against the Pacira Defendants. The Complaints collectively seek, among other relief, (i) injunctive relief preventing the consummation of the transactions contemplated by the Merger Agreement; (ii) rescission and/or rescissory damages in the event the transactions contemplated by the Merger Agreement are consummated; (iii) other damages purportedly incurred on account of defendants’ alleged misstatements or omissions; (iv) disclosure of certain information requested by the plaintiffs; (v) declaratory relief stating defendants violated the Exchange Act; and (vi) an award of plaintiffs’ expenses and attorneys’ fees. The Flexion Defendants have been served with the Wang complaint and the Hart complaint but have not ~~currently~~been served with any of the other Complaints. On November 12, 2021, we filed a ~~party~~Schedule 14D-9/A containing certain supplemental disclosures in order to ~~any material legal proceedings.~~moot the claims alleged in the Complaints. The Flexion Defendants’ deadline to respond to the Wang complaint is December 27, 2021, and the Flexion Defendants’ deadline to respond to the Hart complaint is January 3, 2022. Each of the Flexion Defendants and the Pacira Defendants intend to vigorously defend these actions.

As disclosed in “Item 1A. Risk Factors” in our Annual Report on Form 10‑K for the year ended December 31, 2020, which was filed on March 10, 2021, there are a number of risks and uncertainties that may have a material effect on our business, financial condition, results of operations, and future growth prospects. There areare also additional risks and uncertainties that we are unaware of that may become important factors that affect ~~us.~~us, including as a result of the potential acquisition by Pacira. The following risk factors are either new or have changed materially from those set forth in our Annual Report on Form 10‑K for the year ended December 31, 2020. You should carefully review the risks described below and in our Annual Report on Form 10‑K and in other reports we file with the Securities and Exchange Commission in evaluating our business.

The announcement and pendency of our agreement to be acquired by Pacira may have an adverse effect on our business, operating results, and our stock price and may result in the loss of employees, customers, suppliers, and other business partners.

On October 11, 2021, we entered into the Merger Agreement with Pacira and Purchaser, providing for the merger of Purchaser with and into Flexion, with Flexion surviving the Merger as a wholly owned subsidiary of Pacira. We are subject to risks in connection with the announcement and pendency of the Merger, including, but not limited to, the following:

While the Merger is pending, we are subject to contractual restrictions that could harm our business, operating results, and our stock price.

The Merger Agreement includes restrictions on the conduct of our business prior to the completion of the Merger, generally requiring us to conduct our businesses in the ordinary course, consistent with past practice, and restricting us from taking certain specified actions absent Pacira’s prior written consent, including, without limitation, restrictions on our ability to enter into contracts, acquire or dispose of assets, raise equity capital, incur indebtedness, or incur certain capital expenditures. We may find that these and other obligations in the Merger Agreement may delay or prevent us from or limit our ability to respond effectively to competitive pressures, industry developments, and future business opportunities that may arise, even if our management and board of directors think they may be advisable. These restrictions could adversely impact our business, operating results, and our stock price and our perceived acquisition value, regardless of whether the Merger is completed.

The failure to complete the Merger may adversely affect our business and our stock price.

Consummation of the Merger is subject to certain closing conditions, and a number of the conditions are not within our control and may prevent, delay, or otherwise materially adversely affect the completion of the transaction. We cannot predict with certainty whether and when any of the required closing conditions will be satisfied or if another uncertainty may arise and cannot assure you that we will be able to successfully consummate the proposed merger as currently contemplated under the Merger Agreement or at all. Such conditions include, among other things, (i) valid tender (without withdrawal) of Shares that represent at least one Share more than 50% of the then issued and outstanding Shares; (ii) subject to certain materiality qualifications, the continued accuracy of our representations and warranties, and our continued compliance with covenants and obligations (to be performed at or prior to the closing of the Merger); (iii) the absence of any continuing Material Adverse Effect (as defined in the Merger Agreement) on our business, assets, financial condition, or results of operations occurring after the date of the Merger Agreement; (iv) expiration or termination of any waiting periods applicable to the consummation of the Merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; and (v) the absence of any legal restraints prohibiting the Merger and of certain legal proceedings brought by a governmental entity relating to the Merger.  There can be no assurance that these conditions to the consummation of the Merger will be satisfied, or that the Merger will be completed on the proposed terms, within the expected timeframe or at all.  If the Merger is not completed, we may be subject to negative publicity or be negatively perceived by the investment or business communities and our stock price could fall to the extent that our current stock price reflects an assumption that the Merger will be completed. Furthermore, if the Merger is not completed, we may suffer other consequences that could adversely affect our business and results of our operations, including, but not limited to, the filing of associated litigation, difficulties in raising additional capital or obtaining other financing, damage to relationships with vendors or customers, and loss of key personnel.

The Merger Agreement limits our ability to pursue alternative transactions, which could deter a third party from proposing an alternative transaction.

The Merger Agreement contains provisions that, subject to certain exceptions, limit our ability to (i) directly or indirectly, solicit, initiate, or knowingly facilitate or encourage (including by way of furnishing non-public information) any inquiry regarding, or the making of any proposal or offer that could reasonably be expected to lead to, an acquisition proposal; (ii) engage in, continue, or otherwise participate in any discussions or negotiations regarding, or furnish to any other person any information in connection with or for the purpose of knowingly encouraging or facilitating, an acquisition proposal; (iii) adopt, approve, or enter into any letter of intent, acquisition agreement, agreement in principle, or similar agreement with respect to an acquisition proposal or any proposal or offer that could reasonably be expected to lead to an acquisition proposal; or (iv) waive or release any person from, or fail to use reasonable best efforts to enforce, any standstill obligations relating to an acquisition proposal or any proposal or offer that could reasonably be expected to lead to an acquisition proposal. It is possible that these or other provisions in the Merger Agreement, including a termination fee of $18.0 million payable to Pacira under certain circumstances, might discourage a potential competing acquirer that might have an interest in acquiring all or a significant part of our outstanding common stock from considering or proposing an acquisition or might result in a potential competing acquirer proposing an overall lower per-share consideration amount than it might otherwise have proposed to offer.

If the Merger occurs, our stockholders will not be able to participate in any financial upside to our business after the Merger other than through the CVRs; if the required milestones under the CVRs are not achieved, stockholders will not realize any value from the CVRs.

Upon consummation of the Merger, each issued and outstanding share will be converted into the right to receive (i) $8.50 per Share in cash, net of applicable withholding taxes and without interest, plus (ii) one non-transferable contractual contingent value right (“CVR”) per Share, which will represent the right to receive one or more contingent payments up to $8.00 in the aggregate, in cash, net of applicable withholding taxes and without interest, upon the achievement of specified milestones pursuant to the terms of the Contingent Value Right Agreement in the form attached as Exhibit C to the Merger Agreement (the “CVR Agreement”). Following the consummation of the Merger, whether any of the milestones are achieved will be subject to Pacira’s commercially reasonable efforts and activities, over which our stockholders will have no control, and there is no guarantee that any of the milestones will be achieved. If none of the milestones specified in the CVR Agreement are achieved on or before December 31, 2030, no payment will be made under the CVRs, and the CVRs will expire valueless.

The U.S. federal income tax treatment of the CVRs is unclear. There is no legal authority directly addressing the U.S. federal income tax treatment of the receipt of, and payments (if any) under, the CVRs, and there can be no assurance that the Internal Revenue Service would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the CVRs.

Additional lawsuits may be filed against us and the members of our board of directors arising out of the proposed Merger, which may delay or prevent the proposed Merger.

Additional putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against us, our board of directors, Pacira, Pacira’s board of directors, and others in connection with the transactions contemplated by the Merger Agreement. The outcome of litigation is uncertain, and we may not be successful in defending against any such future claims. Lawsuits that may be filed against us, our board of directors, Pacira, or Pacira’s board of directors could delay or prevent the consummation of the Merger, divert the attention of our management and employees from our day-to-day business, and otherwise adversely affect us financially.

We will incur substantial transaction fees and costs in connection with the Merger.

As of September 30, 2021, we have incurred $0.7 million of expenses and fees for professional services and other transaction costs in connection with the Merger and expect to continue to incur additional significant costs. A material portion of these expenses are payable by us whether or not the Merger is completed. While we have assumed that a certain amount of transaction expenses will be incurred, factors beyond our control could affect the total amount or the timing of these expenses. Many of the expenses that will be incurred, by their nature, are difficult to estimate accurately. These expenses may exceed the costs historically borne by us. These costs could adversely affect our business, financial condition, operating results, and cash flows.

Our existing indebtedness contains restrictions that limit our flexibility in operating our business. In addition, we may be required to make a prepayment or repay our outstanding indebtedness earlier than we expect.

On August 2, 2019, we entered into an Amended and Restated Credit and Security Agreement with Silicon Valley Bank, MidCap Financial Trust, and Flexpoint MCLS Holdings, LLC, or the Credit Agreement, which provides for a term loan of $40.0 million and a revolving credit facility up to $20.0 million. We concurrently drew down the $40.0 million term loan and used $7.7 million of the proceeds to repay the remaining amount owed on our prior credit facility. In February 2020, we drew down $20.0 million from the revolving credit facility. On May 18, 2020, we entered into an amendment to the Credit Agreement pursuant to which we borrowed $15.0 million under a new term loan advance and immediately used the proceeds to repay an equal amount under the revolving credit facility, and the maximum principal amount of the revolving credit facility was reduced from $20.0 million to $5.0 million. On July 30, 2021, we entered into a second amendment, or the 2021 Amended Credit Agreement, to the Credit Agreement, which provides for a term loan of up to $75.0 million, with $55.0 million available at closing and an additional $20.0 million, or the second tranche, available upon positive Phase 1 clinical trial data in either of our two pipeline programs, FX201 and FX301, sufficient to initiate a Phase 2 clinical study, and a revolving credit facility of up to $25.0 million. We concurrently borrowed the $55.0 million term loan, simultaneously used $48.1 million of the proceeds to repay the previously outstanding term loan under the Credit Agreement, and drew down $20.0 million from the revolving credit facility, bringing the total revolver balance to $25.0 million. The 2021 Amended Credit Agreement contains various covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other things:

Under the 2021 Amended Credit Agreement we are subject to a minimum liquidity threshold, such that at any time our liquidity (defined as cash, cash equivalents, and marketable securities held with Silicon Valley Bank and certain accounts receivable as deemed eligible under the 2021 Amended Credit Agreement) is below $100.0 million (if the second tranche is undrawn) or $120.0 million (if the second tranche is drawn), we will become subject to a minimum revenue covenant. The minimum revenue covenant, if it applies in the future, is applied to the trailing six months of net revenue and is determined based on our approved forecast, as determined by the Lenders.

If the revenue covenant becomes applicable to us and we fail to meet it, the commitments under the 2021 Amended Credit Agreement could be terminated and any outstanding borrowings, together with accrued interest, under the 2021 Amended Credit Agreement could be declared immediately due and payable. Additionally, if our liquidity is below $120.0 million, all amounts received from customer collections will be applied immediately to reduce the revolving credit facility. The restrictive covenants in the 2021 Amended Credit Agreement could prevent us from pursuing business opportunities that we or our stockholders may consider beneficial.

A breach of any of these covenants could result in an event of default under the 2021 Amended Credit Agreement. An event of default will also occur if, among other things, a material adverse change in our business, operations, or condition occurs, which could potentially include a material impairment of the prospect of our repayment of any portion of the amounts we owe under the 2021 Amended Credit Agreement. In the case of a continuing event of default under the 2021 Amended Credit Agreement, the lenders could elect to declare all amounts outstanding to be immediately due and payable, proceed against the collateral in which we granted the lenders a security interest under the 2021 Amended Credit Agreement, or otherwise exercise the rights of a secured creditor. Amounts outstanding under the 2021 Amended Credit Agreement are secured by all of our existing and future assets, excluding intellectual property, which is subject to a negative pledge arrangement.

In April 2017, we also issued $201.3 million principal amount of our 3.375% Convertible Senior Notes due 2024, or the 2024 Convertible Notes. The 2024 Convertible Notes will mature on May 1, 2024, unless earlier redeemed, repurchased, or converted in accordance with the terms of the indenture governing the notes. If the 2024 Convertible Notes are not redeemed or repurchased on or before their maturity date of May 1, 2024, we will be required to convert all or a portion of the amounts due under the 2024 Convertible Notes into common stock, which would cause our stockholders to experience additional dilution and could cause our stock price to fall. If specified bankruptcy, insolvency, or reorganization-related events of default occur, or if certain other events of default occur, including a default under the 2021 Amended Credit Agreement resulting in an obligation to repay the indebtedness, and the trustee or certain holders of the 2024 Convertible Notes elect, the principal of, and accrued and unpaid interest on, all of the then-outstanding 2024 Convertible Notes will automatically become due and payable. In addition, if we undergo certain fundamental change transactions specified in the indenture governing the 2024 Convertible Notes, including, but not limited to the consummation of the Merger, the holders of the notes may require us to repurchase their notes at a price equal to 100% of the principal amount of the notes, plus any accrued and unpaid interest.

We may not have enough available cash or be able to raise additional funds on satisfactory terms, if at all, through equity or debt financings to repay or refinance our indebtedness at the time any such repayment or repurchase is required. In such an event, we may be required to delay, limit, reduce, or terminate our product development or commercialization efforts or grant others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our business, financial condition, and results of operations could be materially adversely affected as a result.

COVID-19 will likely continue to have an adverse impact on our clinical trials and further development of our pipeline.

COVID-19’s impact on the healthcare industry is significant and has impacted our on-going clinical trials and may disrupt further development of our pipeline. For example, in April 2020, we temporarily suspended the active Phase 1 clinical trial evaluating the safety and tolerability of FX201. The decision was made in consideration of guidance from the FDA to ensure the safety of trial participants and minimize risk to trial integrity from disruptions caused by COVID-19. In addition, we decided to terminate the Phase 2 trial evaluating the efficacy of ZILRETTA in patients with shoulder OA and adhesive capsulitis, given the small number of patients enrolled in the trial, the uncertainty as to when we would be able to restart the study, and the costs required to maintain it in an inactive status. While we subsequently restarted our Phase 1 clinical trial of FX201 in late May 2020, ~~and we~~ intend to initiate a trial investigating ZILRETTA in patients with shoulder OA ~~in 2021~~following our reassessment of the proposed study design, and have started clinical development of FX301, we cannot guarantee that COVID-19’s impact or restrictions implemented by government agencies or healthcare facilities in response to COVID-19 will not force us to delay, suspend, or terminate these trials, and we cannot predict how access to, utilization of, and efficacy of COVID-19 vaccines may influence such impacts and restrictions. These impacts of COVID-19 will increase the costs of completing clinical development and delay our ability to obtain marketing approval for our pipeline product candidates and ZILRETTA for additional indications.

If we are unable to effectively train, equip, and deploy our sales force, our ability to successfully commercialize ZILRETTA will be harmed.

We are required to expend significant time and resources to train our sales force to be credible, persuasive, and compliant with applicable laws in marketing ZILRETTA for its approved indication. In addition, we must train our sales force to ensure that an appropriate and compliant message about ZILRETTA is being delivered. Due to the COVID-19 pandemic, our MBMs have been using a mix of in-person and virtual interactions with physicians to convey key information about ZILRETTA and aid physicians and their staff in prescribing and obtaining reimbursement for ZILRETTA. While we have attempted to maintain the effectiveness of our sales and marketing efforts, it may not be as effective as in the pre-COVID environment, as access to some providers remains limited. If we are unable to maintain an effectively trained sales force, equip them with compliant and effective materials, including medical and sales literature to help them appropriately inform and educate customers regarding the potential benefits and safety of ZILRETTA and its proper administration, and deploy them in an efficient and productive manner, our efforts to successfully commercialize ZILRETTA could be jeopardized, which would negatively impact our ability to generate product revenues.

Recently enacted and future legislation, including health care reform measures, may increase the difficulty and cost for us to commercialize ZILRETTA and any future products and may affect the prices we may obtain.

The United States and some foreign jurisdictions are considering, or have enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell ZILRETTA and any other products approved for sale profitably. Among policy makers and third-party payers in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality, and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been, and may continue to be, significantly affected by major legislative, congressional, and enforcement initiatives. Moreover, in some foreign jurisdictions, pricing of prescription pharmaceuticals is already subject to government control.

For example, the Patient Protection and Affordable Care Act, as amended, or PPACA, was intended to, among other items, broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the health industry, and impose additional health policy reforms. Among the PPACA provisions of importance to the pharmaceutical industry are the imposition of additional fees, an increase in required rebates and a change in their method of calculation, discounts to eligible beneficiaries under Medicare Part D, expanded discount eligibility for entities under the Public Health Service pharmaceutical pricing program, expansion of the range of existing manufacturer liabilities, expanded eligibility for Medicaid programs, additional reporting requirements, expansion of and enhanced penalties under fraud and abuse laws, and improved market access for follow-on biologic products. There have been legal and political challenges to PPACA. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the PPACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Thus, the PPACA will remain in effect in its current form. It is possible that the PPACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform efforts of the Biden administration will impact PPACA and our business. We expect that PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, as well as additional downward pressure on the price that we receive for any approved product, including ZILRETTA. It is also possible that additional governmental action is taken in response to COVID-19.

The market price of our common stock may be highly volatile, you may not be able to resell your shares at a desired market price, and you could lose all or part of your investment.

The trading price of our common stock is likely to be volatile due to a variety of factors, including the following:

The trading price of our common stock may also be dependent upon the valuations and recommendations of the analysts who cover our company. If our results do not meet these analysts’ forecasts, the expectations of our investors, or any financial guidance or expectations we provide to investors, the market price of our common stock could decline. Our ability to meet analysts’ forecasts (including revenue and profitability), investors’ expectations, and our own guidance or financial expectations is substantially dependent on our ability to increase sales of ZILRETTA and to successfully commercialize ZILRETTA in the United States. Because we have not yet fully commercialized ZILRETTA, we and the analysts who cover our company have limited ability to accurately predict future sales results, and actual results may differ materially from expectations.

In addition, the stock market in general, and the Nasdaq Global Market in particular, has experienced extreme price and volume fluctuations, and we have in the past experienced volatility that we believe has been unrelated or disproportionate to our operating performance. For example, during the first quarter of 2020, the closing price of our common stock ranged from $5.53 to $21.13 per share. Broad market and industry factors may continue to negatively affect the market price of our common stock, regardless of our operating performance. For example, there have been instances of groups of investors buying shares of a company’s stock in order to drive up its market price, thereby causing traders who have bet that the stock price would fall and contracted to sell shares of that stock with a plan to buy those shares after the share price has fallen (i.e., those who have “shorted” the stock) to buy in as well to forestall even greater losses; this is known as a “short squeeze.” These short squeezes have caused extreme volatility in both the stock prices of the companies involved and in the market and have led to the shares of those companies trading at a significantly inflated price per share that is disconnected from the underlying value of the company. Many investors who have purchased shares in those companies at an inflated share price face the risk of losing a significant portion of their original investment, as in many cases the price per share has declined steadily as interest in those stocks has abated. While we do not believe that our common stock has been the target of a short squeeze, there can be no assurance that our common stock will not be impacted by unusual trading activity in the future or that the price of our common stock will not become significantly disconnected from our underlying value.

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans or the conversion of our debt securities, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

We may need significant additional capital in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell such equity securities in one or more transactions at prices, under terms, and in a manner as we may determine from time to time. These sales may result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.

Pursuant to our 2013 equity incentive plan, we are authorized to grant stock options and other equity-based awards to our employees, directors, and consultants. The number of shares available for future grant under this plan automatically increases each year by 4% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our board of directors to reduce the size of any such increase. Currently, we plan to register the increased number of shares available for issuance under this plan each year. If our board of directors elects to increase the number of shares available for future grant by a significant amount each year, our stockholders would experience additional dilution, which could cause our stock price to fall.

If the 2024 Convertible Notes are not redeemed or repurchased on or before their maturity date of May 1, 2024, we will be required to convert all or a portion of the amounts due under the 2024 Convertible Notes into common stock, which would cause our stockholders to experience additional dilution and could cause our stock price to fall.

* Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Flexion agrees to furnish supplementally to the SEC a copy of any omitted exhibits or schedules upon request; provided that Flexion may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act.

34** Pursuant to Item 601(b)(10) of Regulation S-K, certain portions of this exhibit have been omitted by means of marking such portions with asterisks because Flexion has determined that the information is not material and would likely cause competitive harm to Flexion if publicly disclosed.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Delaware		26-1388364
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

10 Mall Road, Suite 301 Burlington, Massachusetts		01803
(Address of Principal Executive Offices)		(Zip Code)


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common stock, $0.001 par value per share	FLXN	Nasdaq Global Market


PART I. FINANCIAL INFORMATION
	Item 1. Financial Statements	3
	Condensed Consolidated Balance Sheets as of ~~March 31,~~September 30, 2021, and December 31, 2020 (Unaudited)	3
	Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended ~~March 31,~~September 30, 2021 and 2020 (Unaudited)	4
	Condensed Consolidated Statements of Changes in Stockholders’ Deficit (Unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the ~~three~~nine months ended ~~March 31,~~September 30, 2021, and 2020 (Unaudited)	6
	Notes to Condensed Consolidated Financial Statements (Unaudited)	7
	Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	2124
	Item 3. Quantitative and Qualitative Disclosures about Market Risk	3035
	Item 4. Controls and Procedures	3136
PART II. OTHER INFORMATION
	Item 1. Legal Proceedings	3237
	Item 1A. Risk Factors	3237
	Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	3343
	Item 3. Defaults Upon Senior Securities	3343
	Item 4. Mine Safety Disclosures	3343
	Item 5. Other Information	3343
	Item 6. Exhibits	3444
	Signatures	3545


	December 31, 2020
(In thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Commercial paper	$	6,890	$	—	$	—		$	6,890
U.S. government obligations		9,997		1		—			9,998
Corporate bonds		50,700		2		(14	)		50,688
	$	67,587	$	3	$	(14	)	$	67,576

	December 31, 2020
(In thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Commercial paper	$	6,890	$	—	$	—		$	6,890
U.S. government obligations		9,997		1		—			9,998
Corporate bonds		50,700		2		(14	)		50,688
	$	67,587	$	3	$	(14	)	$	67,576


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐


	March 31, 2021									September 30, 2021
(In thousands)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Commercial paper	$	8,893	$	—	$	—		$	8,893	$	2,000	$	—	$	—	$	2,000
Corporate bonds		46,690		1		(11	)	$	46,680		3,229		—		—		3,229
	$	55,583	$	1	$	(11	)	$	55,573	$	5,229	$	—	$	—	$	5,229

(In thousands)	For the three months ended March 31,
Operating lease cost	2021		2020
Operating lease cost included in operating expenses	$	513	$	513
Operating lease cost included in inventory		62		57
Total operating lease cost		575		570

Operating cash flows from operating leases		786		818


Year	Operating Lease Obligations (in thousands)			Operating Lease Obligations (In thousands)
2021		1,536			515
2022		1,888			2,087
2023		1,896			2,142
2024		1,938			1,975
2025		815			809
Thereafter		432			422
Present value of imputed interest		(2,257	)		(2,115	)
Total	$	6,248		$	5,835


	Nine Months Ended September 30,
(In thousands)	2021			2020			Change			% Increase/ (Decrease)
Revenues:
Product revenue, net	$	74,090		$	59,242		$	14,848			25.1	%
Operating expenses:
Cost of sales		14,791			12,887			1,904			14.8	%
Research and development		41,487			43,733			(2,246	)		(5.1	)%
Selling, general and administrative		81,993			81,341			652			0.8	%
Total operating expenses		138,271			137,961			310			0.2	%
Loss from operations		(64,181	)		(78,719	)		14,538			(18.5	)%
Other (expense) income:
Interest income		531			584			(53	)		(9.1	)%
Interest expense		(16,156	)		(14,848	)		(1,308	)		8.8	%
Other expense		(1,270	)		(581	)		(689	)		118.6	%
Total other (expense) income		(16,895	)		(14,845	)		(2,050	)		13.8	%
Loss before income taxes		(81,076	)		(93,564	)		12,488			(13.3	)%
Income tax expense		—			495			(495	)	NM
Net loss	$	(81,076	)	$	(94,059	)		12,983			(13.8	)%


	Three Months Ended September 30,								Nine Months Ended September 30,
(In thousands, except for % of sales)	2021			% of Sales	2020			% of Sales	2021			% of Sales	2020			% of Sales
Product revenue, gross	$	30,825		100.0%	$	27,704		100.0%	$	95,283		100.0%	$	68,498		100.0%
Adjustments to product revenue, gross
Provider discounts and rebates		(3,245	)	(10.5)%		(1,329	)	(4.8)%		(9,048	)	(9.5)%		(2,757	)	(4.0)%
Estimate of product returns		(3,421	)	(11.1)%		(136	)	(0.5)%		(3,640	)	(3.8)%		(345	)	(0.5)%
All other		(2,833	)	(9.2)%		(2,575	)	(9.3)%		(8,505	)	(8.9)%		(6,154	)	(9.0)%
Product revenue, net	$	21,326		69.2%	$	23,664		85.4%	$	74,090		77.8%	$	59,242		86.5%


Exhibit number		Description of document
~~3.1~~2.1*		Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc., Pacira BioSciences, Inc., and Oyster Acquisition Company Inc. (Exhibit 2.1, Current Report on Form 8-K, filed with the SEC on October 12, 2021).
3.1		Amended and Restated Certificate of Incorporation of Flexion (Exhibit 3.1, Current Report on Form 8-K, filed with the SEC on February 19, 2014).
3.2		Amended and Restated Bylaws of Flexion (Exhibit 3.2, Current Report on Form 8-K, filed with the SEC on February 19, 2014).
4.1		Form of Common Stock Certificate of Flexion (Exhibit 4.1, Registration Statement on Form S-1 (File No. 333-193233), as amended, filed with the SEC on January 29, 2014).
4.2		Indenture, dated May 2, 2017, by and between Flexion and Wells Fargo Bank, National Association, as trustee (Exhibit 4.1, Current Report on Form 8-K, filed with the SEC on May 2, 2017).
4.3		Form of Note representing Flexion’s 3.375% Convertible Senior Notes due 2024 (included as Exhibit A to the Indenture filed as Exhibit 4.1, Current Report on Form 8-K, filed with the SEC on May 2, 2017).
~~31.1~~10.1		Form of Tender and Support Agreement, dated as of October 11, 2021 (Exhibit 10.1, Current Report on Form 8-K, filed with the SEC on October 12, 2021).
10.2**		Manufacturing and Supply Agreement, dated July 31, 2015, by and between Flexion and Patheon UK Limited.
10.3**		Technical Transfer and Service Agreement, dated July 31, 2015, by and between Flexion and Patheon UK Limited.
31.1		Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
31.2		Certification of the Principal Accounting and Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
32.1		Certification of the Principal Executive Officer and Principal Accounting and Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline eXtensible Business Reporting Language (XBRL) Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)


	Flexion Therapeutics, Inc.

Date: ~~May~~November 12, 2021	By:	/s/ Michael D. Clayman
		Michael D. Clayman
		Chief Executive Officer
		(Principal Executive Officer)


Date: ~~May~~November 12, 2021	By:	/s/ ~~David Arkowitz~~Frederick W. Driscoll
		~~David Arkowitz~~Frederick W. Driscoll
		Chief Financial Officer
		(Principal Accounting and Financial Officer)